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HIV in South Africa is transmitted predominantly through heterosexual sex, with mother-to-
child transmission being the other main route of infection. According to the data that was 
published in 2010 by Statistics South Africa, an estimated 40,000 children in South Africa are 
infected with HIV each year, reflecting poor prevention of mother-to-child transmission.  
Human breast milk through breast-feeding is an essential source of nutrition and it also offers 
protection from respiratory and gastrointestinal infections. Breastfeeding has been shown to 
lower the incidence of other infectious diseases during the first year of life. Breast-feeding 
also maintains the maternal-fetal immunologic link after birth which may favour the 
transmission of immuno-competence from the mother to her infant.  
Milk molecules such as mucins, antibodies, bactericidal enzymes like lysozymes and fatty 
acids that lyse bacteria, viral particles and bacterial peptides, offer anti-microbial activity in 
milk. Despite human breast milk being rich in anti-microbial substances, such as mucin, that 
protect against pathogens and viruses, it remains a significant route of HIV transmission from 
mother to child. This leaves the question of the ability of the breast milk and its mucin 
components to protect against the human immunodeficiency virus. 
The objectives of the study were to isolate, purify, identify and investigate the anti-HIV-1 
activity of crude breast milk particularly the human milk fat globule material (MFGM) and its 
purified mucin components, in HIV positive patients (n = 20) compared with those who are 
not infected (n = 20). This study also tested the effect that heat (80
o
C, 10 min) might have on 
breast milk which might release the milk mucins and consequently have an inhibitory effect 
on HIV-1.  
Breast milk was extracted and solubilised by stirring in 6M guanidinium chloride and a 
cocktail of protease inhibitors in a ratio of 5 parts breast milk and 1 part guanidinium chloride. 
The milk fat globule membrane was obtained after the human breast milk was defatted by 
centrifugation at 3 000g for 1 hour at 4
o
C.  Following Sepharose CL-4B gel filtration, the 
identity of mucins MUC1 and MUC4 was confirmed by Western blotting. MFGM-I peaks 
from both groups were further purified by isopycnic density gradient centrifugation in 
caesium chloride. Amino acid composition on the purified milk mucins of the MFGM-I was 















In order to determine whether human breast milk mucin had any variation of MUC1 and 
MUC4, breast milk mucin glycoproteins were separated based on charge using the HPLC ion-
exchange chromatography before applying the fractions to a 0.7% agarose gel electrophoresis, 
and then blotted onto the nitrocellulose which was probed with antibodies against MUC1 and 
MUC4. The  anti-HIV activity of the milk and purified mucins was determined by an in 
vitro HIV-1 neutralisation assay that exploits the use of “pseudo-viruses”. 
The SDS-PAGE gels stained with PAS for carbohydrates from the non-purified HIV positive 
MFGM and HIV negative MFGM showed the presence of mucin bands on top of the stacking 
gel as well as those that have entered the running gel. The mucins that have entered the 
running gels for both groups seem to vary in intensity of staining and are in the region of 
molecular weight (Mr ~ 100-220kDa). The HIV positive non-purified MFGM seemed to have 
more intense staining than the HIV negative MFGM. 
 
When mucins were isolated from the MFGM by Sepharose CL-4B gel filtration, the elution 
profiles for the HIV positive group and HIV negative group showed that the MFGM material 
have two mucin rich peaks. The first peak MFGM-I eluted in the void volume (Vo) whilst the 
second peak MFGM-II eluted in the included volume (Vi) of the column.  The HIV positive 
samples had two large distinct peaks while the HIV negative ones showed one small peak and 
one large peak. When the peaks were separated on SDS-PAGE, the MFGM-I peaks from both 
groups showed more intensely stained mucins than the MFGM-II peaks. In both groups, 
MFGM-I peaks had less contaminant proteins than MFGM-II.  
 
Western blot analysis of the semi-purified material eluting from the Sepharose 4B gel 
filtration column confirmed the presence of MUC1 and MUC4 in samples from both HIV 
positive and HIV negative groups. The staining on the blots was more intense for the Vo 
(MGFM-1) than the Vi (MGFM-II) material for both MUC1 and MUC4, again for both HIV 
positive and negative groups. Overall there was more detectable material on the Western blots 
for mucins from the HIV positive group than that for the HIV negative group. However, 
except for intensity of staining, no clear difference was seen between the HIV positive and 
negative groups, but rather an inter-individual variation within each group with respect to the 
















The MFGM-I from both groups were further purified by caesium chloride isopycnic density 
gradient centrifugation.  Both purification profiles showed a clear separation between the 
lower density proteins and the higher density mucin fractions which were assayed by PAS. To 
confirm purification, the fractions with the highest mucin peaks were separated on SDS-
PAGE gel before staining with PAS which showed that the mucins were present in both 
groups at the top of the running gel. The SDS-PAGE gel was also stained with Coomassie 
Brilliant Blue R-250 which showed detectable proteins, again at the top of the running gel. 
The absence of bands within the running gels shows that the mucins were successfully 
purified. 
 
There was no difference in the content of amino acid between the two groups. For the HIV 
positive group, the amount of serine threonine and proline added up to 41% of the MFGM-I, 
while they added up to 37% of the MFGM-I for the HIV negative.  
 
Possible changes in the glycosylation of milk mucins in the two groups, namely the HIV 
positive and negative groups were investigated by using a combination of anion-exchange 
HPLC and agarose gel electrophoresis. The PAS profile for the HIV positive MFGM fractions 
from the HPLC shows evidence of two major population groups and one other minor 
population that is not as distinct. These fraction samples from the HPLC were subjected to 
agarose gel electrophoresis before blotted onto a nitrocellulose membrane then probing with 
anti-MUC1 and anti-MUC4 antibodies. When probed with anti-MUC1, the HIV positive 
fractions showed the presence of three distinct populations of MUC1. Two visible 
electrophoretic patterns were observed on the Western blots, the first pattern confirms 
population I, while the second pattern verifies the presence of population II. The minor 
population III was observed as smears of MUC1. The results showed a variation in amounts, 
charge difference and electrophoretic mobility for MUC1 in the HIV positive group compared 
to the HIV negative group.  
 
When probed with anti-MUC4 antibody, the HIV negative fractions confirmed the presence 
of MUC4 to be present in population I and III. However, the variation seen in MUC1 in the 
HIV positive group was not as marked for MUC4 in this group.   
 
The PAS profiles of the HIV negative MFGM fractions shows that the mucins do not vary as 















PAS profile, population II was observed as a minor peaks present. Another minor peak was 
observed which could be another potential population. When probed with anti-MUC1, the 
HIV negative fractions showed that MUC1 was detected on the fractions of population I. 
When the blot was probed with anti-MUC4 antibody, MUC4 was detected on fractions which 
formed population I. There seemed to be faint traces of MUC4 detected on fractions of the 
slight peak observed on the PAS profile which could potentially form population II. Neither 
MUC1 nor MUC4 were detected in the third minor peak. 
 
The anti-HIV activity of the crude breast milk, purified milk mucins, and heated milk from 
the HIV positive (n=16) and HIV negative (n=16) groups were tested against the Du422.1 
pseudovirus using the reporter gene assay in TZM-bl cells. The crude breast milk samples 
showed 60% neutralisation for the HIV positive samples, while the HIV negative milk 
neutralised 40%. The purified milk mucins from the HIV positive group neutralised 50% of 
the viral activity, while the HIV negative mucins had much lower neutralisation efficacy with 
35% neutralisation. Increased neutralisation of viral activity was seen for the heated milk 
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In South Africa alone in 2004, between 4.68 and 7.03 million people were living with 
HIV/AIDS, of which 55% were females (Habte et al., 2008). An estimated 1.9 million [1.6 
million–2.2 million] people were newly infected with HIV in sub-Saharan Africa in 2008, 
bringing to 22.4 million [20.8 million–24.1 million] the number of people living with HIV 
(UNAIDS, 2009). HIV in South Africa is transmitted predominantly through heterosexual 
sex, with mother-to-child transmission being the other main route of infection. The national 
transmission rate of HIV from mother to child is approximately 11%. An estimated 40,000 
children in South Africa are infected with HIV each year, reflecting poor prevention of 
mother-to-child transmission (PMTCT) (UNGASS, 2010 and statistics South Africa, 2010). 
Therefore, whilst there is an urgent need for the development of a safe, natural, and affordable 
vaccine, other initiatives to develop therapies and preparations are of utmost importance. 
Previous work in our laboratory (Habte et al., 2007, Habte et al., 2008) has shown that the 
purified mucin component of breast milk (MUC1 and MUC4) inhibits HIV-1 virus in an in 
vitro p24 assay, whilst the crude milk preparation does not. This finding could explain why 
infants acquire the virus through mother-child-transmission during breast feeding. This study 
will undertake to statistically verify these findings using an HIV-1 neutralization assay. 
Although this study did not look at the mechanism of inhibition, there is a suggestion that the 
mucins aggregate the virus purely by physical entanglement through a charge interaction with 
carbohydrate side-chains considering that mucins have a high density of negative charges 
through sialic acid and sulphate residue (Habte et al., 2007). This hypothesis, however, has 
not yet been proven, and thus requires further investigation. 
In this study, a comparison of the potential inhibitory role of mucins in breast milk of HIV 
positive individuals has also been made and did not show any differences in the inhibition 
from the HIV negative group. However, variation in the electrophoretic behaviour of the 
mucins from the HIV positive group and HIV negative groups was noted. Our laboratory has 















salivary mucins inhibit the HIV-1, salivary mucus and mucins from HIV positive individuals 
do not (Habte et al., 2010). 
Breastfeeding has been reported as an important factor in protection against enteric infection 
with various pathogens. Numerous studies have recorded that children who are breast fed 
undergo substantially fewer total episodes of gastroenteritis compared with infants who are 
bottle fed (Yolken et al., 1992). Whilst human breast milk is rich in components, such as 
mucin, that have been reported to protect against pathogens and viruses, there is still a need to 
balance the protective effect of breast feeding against other competing causes of infant 
mortality and the low but ongoing risk of infant HIV acquisition via breast milk.  
 
1.2 Human breast milk  
 
As an essential food for newborn mammals, milk is a natural emulsion in which lipids are 
present in the form of small droplets called fat globules (as shown on Figure 1.1) (Lopez et 
al., 2010) with diameters of 1 to 10um (Schroten et al., 1992) that are coated with a protective 
layer generally known as the milk fat globule membrane (MFGM) and which represents 3-4% 
of the total volume of milk (Wilson et al., 2008). Human breast milk contains protein, fat, 
carbohydrates and minerals. The milk also c ntains numerous biologically active compounds 
such as lactoferrin, lysozyme, secretory leukocyte protease inhibitors, -casein, 
oligosaccharides, glycolipids, glycoproteins, mucins and glycosaminoglycans, which protect 
breast-fed infants from bacteria, viruses and toxins (Habte et al., 2007).  
 
The milk lipids are secreted out from the mammary gland cells and then enclosed by the 
MFGM in the apical-cell membranes of mammary secretory cells (Shimizu et al., 1986), 
where they are released, together with the membrane bound proteins (i.e. mucin 
glycoproteins, including the transmembrane mucins) from the cells by budding (Wilson et al., 
2008). 
 
The milk lipids contain fat soluble vitamins, as well as essential and non-essential fatty acids 
and cholesterol for construction of membrane throughout the body (Buchheim et al., 1988). 
The milk lipids are natural vehicles that deliver the triglycerols (~98% of total lipids and an 
important source of energy) and biologically active molecules such as polar lipids and 
















The MFGM consists of a complex mixture of glycoproteins (20-60%), glycerophospholipids 
(15-33%), sphingolipids, glycolipids, triacylglycerols, sterols (0.3% of milk lipids), enzymes 
and other minor components (Lopez et al., 2010). This membrane prevents flocculation and 
coalescence of lipid droplets and protects the fat against lipolysis (Vanderghem et al., 2008). 
The glycoproteins in MFGM act as specific bacterial and viral ligands which contribute to the 
prevention of pathogenic organisms from attaching to the intestinal mucosa in the stomach of 
infants(Wilson et al., 2008).     
 
Figure 1.1 Origin and structure of the milk fat globule membrane (MFGM) reproduced from Lopez 
et al., 2010 (A) Schematic representation of the pathways for the intracellular origin, growth and secretion of 
milk fat globules which are surrounded by the MFGM. (B) Structure of the MFGM showing the lateral 
segregation of sphingomyelin and cholesterol in Lo domains surrounded by the fluid matrix composed of 

















Mucus is a complex, viscous and sticky secretion synthesized by specialized goblet cells of 
the columnar epithelium that lines the major internal tracts of the body that are exposed to the 
external environment. This includes the respiratory, reproductive and oculo-rhino-
otolaryngeal tracts. Mucus is the major organic secretion in the stomach and duodenum where 
it protects against corrosive gastric juices (Allen, 1983). Malfunctioning of mucus has been 
implicated in the etiology of many diseases, such as peptic ulceration, ulcerative colitis, 
bronchitis, infertility and external disorders of the eye (Allen, 1983). 
 
The gel-like mucus shows properties both of a liquid (spontaneous flow by gravity, annealing 
or reclosure of cuts and interruption) and a solid (deformation is resisted, elasticity, 
adherence) (Gevers, 1987). The sliminess and stickiness of the mucus is dependent on the 
mucous glycoproteins (mucins) (Carlstedt et al., 1983). Crude mucus is composed primarily 
of 95% water, but also contains glycoproteins, salts, lipids such as fatty acids, phospholipids 
and cholesterol. It also contains proteins such as lysozyme, immunoglobulins, defensins, 
growth factors and trefoil factors which serve a defensive purpose (Gipson et al., 1997). 
However, the main component responsible for its viscous and elastic gel-like properties is the 
mucous glycoprotein (mucin) (Bansil et al., 2006). 
 
The crude mucus layer on epithelia ensures the hydration of the superficial epithelium. Mucus 
gels are versatile and have different roles in various parts of the body. For example, mucus 
gels in the stomach protect from strong acid and from potent proteases. It facilitates the 
movement of food and hard faecal pellets through the gastrointestinal tract. It protects the 
alveoli by trapping dust particles and other objects in the inhaled air in the tracheo-bronchial 
tubes. Mucus in the gall bladder protects the underlying epithelium against a concentrated 
mixture of surface-active chemicals. Saliva mixes with chewed food and aids in its 
homogenization and lubrication.  
 
Mucus is the first barrier against pathogens. Nutrients and enteric drugs must interact and 
diffuse through mucus which acts as a permeable gel layer, in order to be absorbed and gain 
access to the circulatory system and their target end organs (Bansil et al., 2006). In addition to 
















1.4 Mucus renewal and viscosity 
 
Mucus is continuously produced from the epithelial surface in the gut, and lost to the lumen 
during renewal (Sababi et al., 1995). Under normal conditions, the mucus blanket is 
maintained and renewed by the slow, continuous release of mucin from individual goblet cells 
throughout the epithelium. The secretion occurs by conventional exocytosis: the intermittent 
fusion of a single mucous granule membrane and the apical plasma membrane (Specian et al., 
1980). 
 
The mucus gel is maintained by multiple interaction types (Taylor et al., 2003) and the mucin 
structure affects the potential inter-molecular interaction. However, there is no information as 
to how structural and compositional differences in the component mucins relate to the 
rheology (physical) and functional properties of the mucus gels (Taylor et al., 2004). 
 
The erosion of the mucus gel layer at its luminal surface by proteases and mechanical 
sloughing (from a motile gut, passage of faeces, etc.) is balanced by secretion of new mucus 
to maintain the thickness of the adherent gel layer seen in vivo (Allen et al., 1998), thus 
maintaining a dynamic balance between synthesis and degradation of the epithelial surface.  
 
1.5 Definition of Mucins  
 
Mucins are mucous glycoproteins that are found in the crude mucus gels that line the 
epithelial surfaces of the internal tracts of the body or at the cell surface of epithelial cells in 
the glandular ducts and other epithelia (Desseyn et al., 2008) and are heavily O-glycosylated. 
They differ structurally and chemically from serum glycoproteins and connective tissue 
proteoglycans. These glycoconjugates contain galactose, fucose, N-acetylglucosamine, N-
acetylgalactoamine and sialic acid, but no uronic acid and only traces of mannose (Allen, 
1983). 
 
 These large polymeric molecules contribute to the viscoelastic gel properties of mucus 
(Andersch-Björkman et al., 2007). The high Mr~ glycoprotein mucins contain
 
at least one and 
sometimes multiple protein domains that are
 
sites of extensive O-glycan attachment (mucin 
domains).
 
Thus, the composition of these glycoproteins is dominated by
 
carbohydrates, which 
can total in some cases to as much as 80% of
 















2004). The mucin linear flexible macromolecules have a Mr~ of approximately 2 x 10
6
 and a 
mucin subunit has a Mr ~ of 5 x 10
5 
kDa consisting of a heavily glycosylated backbone with 
one or two “naked” regions of peptide with little or no glycosylation at either end (Kornelia et 
al., 1997, Andersch-Björkman et al., 2007). These mucin subunits are linked by disulphide 
linkages that are susceptible to reductive disruption by thiols such as 2-mercaptoethanol or 
dithiothreitol (DTT). The regions on the subunit that have no glycosylation are prone to 
proteolysis by enzymes such as trypsin, and the products of digestion are referred to as T-
domains. T-domains make up a subunit and subunits make up the polymeric mucin (Kornelia 
et al., 1997). These T- domains have a high content of serine, proline and threonine and are 
resistant to further proteolysis, the protein core being shielded by carbohydrates. 
 
1.6 Mucin protein backbone (Apomucin) 
 
The apoprotein is the protein core without the carbohydrate of the mucin which makes up 
20% of the molecular mass, and is made up of two regions. The central glycosylated mucin 
domain, also called the PTS domain, is made up of tandem repeats (TR) which are rich in 
serine, threonine and proline (STP repeats).
 
These TR domains make up more than 60% of the 
total amino acid content. Serine and threonine provide a high number of attachment sites for 
O-linked carbohydrates (Andersch-Björkman et al., 2007), with N-acetylgalactosamine (Gal-
NAc) the first sugar to be attached (Verma and Davidson, 2004). The second region of the 
apomucin (the protein core without the carbohydrate) is located at the amino (N) and carboxyl 
(C) terminals which have few O-glycosylation and N-glycosylation sites; this region has a 
high proportion of cystene. These domains are important for the disulfide-mediated 




Figure 1.2 A secretory mucin glycoprotein depicting a MUC protein backbone and its O-glycans. 
Made up of the NH2-terminal domain (blue), central domain with tandem repeat containing serine, threonine and 
















1.7 Mucin O-glycans 
 
Mucin-type O-linked glycosylation is initiated in the cis to trans golgi apparatus by the post 
translational addition of N-acetylgalactosamine (Gal-NAc) to the hydroxyl group of serine 
and threonine (Rottger et al., 1998) catalyzed by peptidyl Gal-NAc transferase. The 
incorporation of Gal-NAc gives rise to the simplest known O-glycan structure which serves as 
a scaffold for these O-glycans. The attachment of the sugar residues to the initial Gal-NAc 
results in the formation of the core structures, which can then be elongated to form complex 
structures (Beum et al., 2003).  
 
Oligosaccharide side chain can be elongated by the sequential addition of the sugars such as 
galactose, sialic acid, fucose, traces of mannose and sulphates (Rottger et al., 1998), via 
various core structures, each reaction being catalyzed by specific glucosyltransferases 
(Burchell et al., 1999). Terminal sugars such as sialic acid and sulphates that are attached to 
Gal-NAc impart negative charges to the mucins, whereas fucose imparts hydrophobicity 
(Forstner and Forstner, 1994). O-glycans can be classified on the basis of their core structures 
which differ based on the sugars that are attached to the protein-bound N-acetylgalactosamine 
residue (Fakuda, 2002). These glycans transport water so that the aqueous phase surrounding 
mucins is viscous (Patton et al., 1999). 
  
1.8 Mucin genes and their classification 
 
Approximately 12 mucin genes (designated MUC) had been identified, cloned and partially 
sequenced in humans by the year 2000  (Vinall et al., 2000) and the number of identified 
genes had increased to 19 by the year 2006 (Bansil et al., 2006). Only three MUC genes 
(MUC1, MUC2 and MUC5B) have been totally sequenced due to the difficulty of accurately 
assembling the large size central tandem repeats (Bansil et al., 2006).  
 
Based on their amino acid sequence and chromosomal localization and form, human mucins 
are classified into three classes; gel-forming secreted, secreted but non-gel-forming and trans-
membrane mucins. The families of four genes on chromosome 11p15.5 (MUC2, MUC5AC, 
MUC5B, and MUC6) are thought to encode the major gel-forming mucins. These secreted 
mucins impart gel forming properties to crude mucus gels that adhere to the epithelium of the 















MUC4, MUC11, MUC12, MUC13, MUC16 and MUC20 glycoproteins are membrane 
associated and have a dual function of protection as well as signaling, cell-to-cell contact and 
possibly differentiation. MUC7, MUC8 and MUC9 are secreted mucins that are non-gel 
forming (Mall et al., 2008, Vinall et al., 2000). These MUCs are packed into mucous granules 
and secreted to the surface for the formation of a mucous layer that protects the epithelial 
tissues from both physical and mechanical elements.  
 
1.8.1      Large, secreted and gel-forming mucins 
 
Secreted mucins are large (≈2MDa).
 
They polymerise through disulphide, ionic and 
hydrophobic interactions
 
with proteins as well as other mucins. The genes of several secreted
 
mucins (MUC2, MUC5AC, MUC5B and MUC6) clustered
 
on chromosome 11p15.5 contain 
domains with significant homology
 
to von Willebrand factor D domains. This is because of 
their high content of cysteines which acts as sites for
 
oligomerization (Callaghan et al., 2001). 
The cysteines in the C-termini of these mucins induce polymerisation via disulphide bonds 
which contribute to their large size and gel-forming properties (Van Seuningen et al., 2000). 
 
1.8.2 Small, secreted and non gel-forming mucins 
 
Non gel-forming secreted mucins (MUC7, MUC8 and MUC9) are small and have a simpler 
structural organisation (Moniaux et al., 2001), which differ from the gel-forming mucins as 
they lack cysteine rich domains. MUC7 is found on chromosome 4q13.3 and MUC8 on 
chromosome 12q24.3 (Shanker et al., 1997). There is little information on MUC8 and MUC9 
glycoproteins. However, MUC7 has been well characterised, particularly in saliva. 
 
1.8.3 Membrane-bound mucins 
 
Membrane-tethered mucins (MUC1, MUC3, MUC4, MUC11, MUC12,
 
MUC13, MUC15, 
MUC16, MUC17 and MUC20)( Mall et al., 2008), which contain short cytoplasmic tails in 
association with the cytoskeletal and cytosolic adaptor proteins are bound to cells by an 
integral trans-membrane domain (Rose et al., 2001, Pallesen et al., 2002). MUC1, MUC4 and 
MUC16 are the best characterised transmembrane mucins with MUC16 being the least well 
characterised of the three, owing to the difficulty in analysing a protein of its enormous size. 















1.9 Biosynthesis of mucins  
 
Mucin biosynthesis is reported to start in the nucleus where the mucin or MUC gene 
expression is activated by the transcription factors and translated into MUC proteins in the 
ribosomes (Dekker and Strous, 1990). Mucin monomers are synthesized in the ribosome and 
are N-glycosylated in the endoplasmic reticulum and form disulphide-linked dimers.  
 
Once in the golgi complex, dimeric mucin precursors are O-glycosylated, sulphated and 
assembled into disulphide-bonded oligomers/multimers. Post glycosylation, these dimers are 
polymerized to form mucins (Sheeehan et al., 1999, 2000), which get packaged in a 
condensed manner, into secretory granules (Perez-Villar et al., 2005).  
 
    
 
Figure 1.3 The Model of biosynthesis and secretion of mucin glycoproteins in a goblet or mucus cell. 
Rose et al., (2006) and Perez-Villar (2007). Mucins are produced by both goblet cells in the surface epithelium 
and mucous cells in the submucosal glands (Svitacheva et al., 2001). In the goblet cells of epithelium, mucins 
are synthesized and stored in cytoplasmic membrane-bound granules. Upon appropriate stimulation, the granule 
translocates to the cell periphery, where the granule membrane fuses with the plasma membrane and the contents 
of the granule (mucin) is released into the lumen via the process of exocytosis (Park et al., 2008,  Perez-Vilar et 
al., 2007). 
 
Transmembrane mucins apoprotein undergoes a proteolytic cleavage event after translation, 















of the large repeat array-containing extracellular domain, linked by non-covalent, SDS-
sensitive bonds to the much smaller protein molecule, which include the trans-membrane and 
cytoplasmic domains (Baruch et al., 1999).  
 
1.10 Breast milk mucins 
 
Reports indicated that there are two human milk mucins, namely MUC1 which is best 
characterised and the second milk mucin previously called MUCX which is more heavily 
glycosylated and has a higher apparent molecular weight (Rossi et al., 1996).  
 
 Reports have demonstrated MUCX to be MUC4 (Zhang et al., 2005). About 70% of mucins 
are present in the fat globule membrane (cream fractions) and the rest associated with the 
skim milk (Habte et al., 2007). The milk mucin is an integral membrane component, unlike 
those secreted by goblet cells in the lining of the intestine, airways and reproductive tract 
(Habte et al., 2007). Both MUC1 and MUC4 in milk are reported to have a potential role in 
pathogen adhesion (Wilson et al., 2008). The peptide core of the MUC1 extracellular domain 
ranges in size from 120-300kDa, which can more than double with full glycosylation whilst 





















MUC1 is an integral membrane protein rather than a simple secreted mucin that has been 
studied the most as it is the first mucin to be cloned (Govindarajan and Gipson, 2010). MUC1 
is the only mucin that characteristically is expressed by normal breast epithelium (Diaz et al., 
2001). MUC1 and MUC4 are expressed in large quantities in both the late pregnant and 
lactating mammary glands, whereas the virgin mammary glands produce little or no MUC1. 
MUC1 is also found in the uterus where it offers protection against pathogens. 
 
1.10.1.1 Structure of MUC1 
 
Full length MUC1 is synthesized as a single polypeptide chain which undergoes an early 
proteolytic cleavage in the endoplasmic reticulum, creating heterodimer fragments that remain 
associated during its post-translational processing and transport to the cell surface (Ligtenberg 
















MUC1 has a molecular weight between 130-300 kDa. The full length cDNA encodes a 
protein that has a large extracellular domain (1000-2200 amino acids) (Gendler, 2001) which 
is extensively glycosylated with a variable number of tandem repeats. The larger fragment has 
the N-signal sequence and the VNTR domain of 20-100 repeats of the human sequence 
GSTAPPAHGVTSAPDTRPAP (Hattrup and Gendler, 2008). In addition to O-linked 
glycosylation, MUC1 contains five consensus sites for N-linked glycan addition in a non-
repetitive sequence adjacent to the single trans-membrane domain (Altschuler et al., 2000).  
 
MUC1 also has a smaller fragment that is collectively called MUC1-CT. The MUC1-CT 
consists of three parts, an extracellular stem region of 58 residues (with multiple O- and five 
N- glycosylation sites), a short transmembrane domain, and the 72 amino acids CT (Hattrup 
and Gendler, 2008) which contain conserved phosphorylated tyrosines that bind to kinases 
(Lacunza et al., 2009). The core peptide of the three combined domains is 14kDa, which 
increases in size to 25-30kDa post glycosylation and phosphorylation (Hattrup and Gendler, 
2008). 
 
When MUC1 is characterised with respect to its amino acid and carbohydrate composition, it 
is found to be rich in serine, threonine and proline. It is also estimated to contain 50% 
carbohydrate, 30% of which is sialic acid (Patton et al., 1995).  
 
In MUC1 oligosaccharide, galactose is added to the initial GalNAc to form a core 1 structure. 
In normal breast epithelial cells, core 1 is converted to core 2 by the addition of N-
acetylglucosamine. This reaction is catalysed by the enzyme core 2 β1,6-N-
acetylglucosaminyltransferase. Core 2 is then extended by the addition of polylactosamine 
units.  In breast carcinomas however, conversion of core 1 to core 2 is reduced, resulting in 
the O-glycans on the tumour associated MUC1 being shorter and less complex (Burchell et 
al., 1999). 
 
1.10.1.2 Functions of MUC1 
 
MUC1 is a tethered transmembrane which can act as a second line of defence. It acts as a 
sensor of any environmental disturbances and signals the information to the interior of the cell 















and extended conformation may block cell-cell interaction. It has also been shown to have the 
ability to bind bacteria in human breast milk (Gendler, 2001). 
  
MUC1 has long polylactosamine chains in lactating mammary glands, which hinder the 
binding of peptide reactive antibodies. MUC1 plays a crucial role in regulating many cellular 
functions, including cell proliferation and apoptosis of T-cells. The membrane bound MUC1 
is involved in cell signalling, immunoregulation and inhibition of cell–cell and cell–matrix 
adhesion (Rakha et al., 2005). 
 
In addition to mechanical functions, the MUC1 cytoplasmic tail has been shown to compete 
for or interact with β-catenin through a similar motif found in E-cadherin thus inhibiting the 
formation of E-cadherin/ β-catenin complex (Rakha et al., 2005). MUC1 may participate in 
tumour cell detachment, invasion and metastases and may be associated with aggressive 
tumour behavior and poor prognosis. Through its cytoplasmic domain, phosphorylated MUC1 
associates with other signal molecules such as Grb2/SOS which are signaling mediators of 
tyrosine kinase receptors. This suggests a potential role for MUC1 in cell signaling (Pandey et 
al., 1995, Baruch et al., 1999). In addition, co-localization and interaction between MUC1 
and EGFR family members have also been reported (Rakha et al., 2005). 
 
1.10.1.3 MUC1 as a pathological marker 
 
Modifications of human mucins have been associated with certain diseases. Diseases such as 
cystic fibrosis, malignancies of the gastrointestinal or respiratory tracts are associated with 
dramatic changes in mucin composition and production (Bolscher et al., 1995). The rate and 
level of MUC1 production in human breast milk is known to be an important marker in 
metastatic breast cancer progression (Sekine et al., 1985). It has been reported that aberrant 
expression of MUC1 in patients with ductal hyperplasia with atypia and especially in ductal 
carcinoma in situ of the breast are at higher risk for subsequent development of invasive 
breast carcinoma (Mommers et al., 1999). 
 
Furthermore, the expression of MUC1 in colorectal carcinoma is a valuable indicator of poor 
prognosis in Caucasian patients as opposed to those of African American descent (Manne et 















prognostic impact (Sakamoto et al., 1997). Other studies have reported MUC1 to be a marker 
for some carcinomas such as those of the pancreas (Rhaka et al., 2005). 
                                 
1.10.2 MUC4 
 
MUC4 is a transmembrane mucin that is expressed in the ciliated and goblet cells of the 
trachea and brochus. Human MUC4 is the homolog of the rat sialomucin complex (SMC) 
(Price-Schiavi et al., 1998). The human MUC4 and rat SMC differs from each other in that 
the SMC lacks the 16 amino acid repeat on the Ascites sialoglycoprotein-1 (ASGP-1) which 
is the defining characteristic of MUC4. 
 
Beyond the respiratory tract, MUC4 is expressed in the epithelial tissues of the stomach, 
breast, endocervix, colon (Damera et al., 2006), uterus, ovary, salivary gland, prostate, 
thyroid, mammary gland, esophagus, testis and placenta (Zhang et al., 2005). MUC4 is also 
found in secreted fluids like tears (Govindarajan and Gipson, 2010) and has been proposed to 
be MUCX described in human milk (Zhang et al., 2005). 
 
1.10.2.1 Structure of MUC4 
 
Human MUC4 was originally cloned and sequenced from an airway cDNA library. MUC4 is 
similar to MUC1 in that it is a hetero-dimeric multi-functional glycoprotein encoded by a 
single gene. Structurally, it consists of a large 850kD membrane bound MUC4α subunit  
which is O-glycosylated  and it is also  a homolog of ASGP-1, which is tightly, but 
noncovalently bound to a smaller 80kD trans-membrane MUC4β subunit which is N-
glycosylated and is also known as ASGP-2 (Damera et al., 2006, Wilson et al., 2008) . The 
larger extracellular domain of the MUC4α contains an N-terminal region comprised of a 
sequence of imperfect repeats and a tandem repeat region of 16 amino acids. This 
extracellular domain also contains a cysteine-rich site, a nidogen homology sequence (NIDO), 
the adhesion associated domain, AMOP and a von Willebrand factor type D (VWD) sequence 
close to the transmembrane domain (Govindarajan and Gipson, 2010). The EGF-domains are 


















1.10.2.2  Functions of MUC4 
 
MUC4 binds to ErbB2 via its EGF-like domain. Post MUC4-ErbB2 binding, phosphorylation 
of p38 MAPK is stimulated. This promotes cell survival and differentiation. In cancer, it is 
hypothesized that this MUC4-ErbB2 complex protects cancer cells from undergoing apoptosis 
(Govindarajan and Gipson, 2010). MUC4 also has a possible function as a growth regulator 
due to the fact that ASGP-2 can bind receptor tyrosine kinase p185
neu 
(Rossi et al., 1996). 
ASGP-1 provides anti-recognition and anti-adhesive properties which may be important to the 
high metastastic capacity of certain cancers in ascites cells (Price-Schiavi et al., 1998). 
 
1.10.2.3 MUC4 as a pathological marker 
 
As previously stated (Bolscher et al., 1995), mucins can potentially influence pathological 
classification, diagnosis and prognostication of neoplasia. For example, it has been confirmed 
that MUC4 is absent in normal pancreas and chronic pancreatitis, but is highly raised in 
human pancreatic cancers which are on the increase worldwide with a survival rate ranging 
from 4 to 6 months (Andrianifahanana et al., 2001). MUC4 is a potential candidate marker for 
early diagnosis of epithelial ovarian carcinoma which is detected in the early-stage tumor 
samples and may be utilized in combination with MUC16 to achieve greater sensitivity for the 
detection of late stage tumours (Chauhan et al., 2006). 
 
1.11 Anti-infective properties breast milk and milk mucins 
 
Human breast milk is an essential source of nutrition and it also offers protection from 
respiratory and gastrointestinal infections. Molecules found in milk such as antibodies, 
bactericidal enzymes like lysozyme and fatty acids that lyse bacteria and viral particles and 
bacterial peptides offer anti-microbial activity. While breast milk might offer many benefits, it 
should be noted however that there is a significant risk of mother-to-child transmission of 
HIV-1 through breast-feeding (Nicoll et al., 2000).  Lactoferrin, but not casein or casein 
peptides, has been shown to be inhibitory to HIV virus (Berkhout et al., 2002), while the 
undigestible fucosylated and sialylated oligosaccharides conjugated with protein (mucins) 
may inhibit the adhesion of diarrheal pathogens such as the Rotavirus to the host receptor. 
The mucin fraction of the milk also inhibits the adherence of S-fibriated E.coli to their 















HIV, studies by Newburg (1995) have shown that milk also contains glycosaminoglycan 
moieties that prevent the binding of HIV envelope glycoprotein. Another study demonstrated 
that MUC1, which is another Lewis-X factor abundantly present in milk, specifically bound to 
DC-sign (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin) 
on DC and effectively blocked DC-sign mediated HIV-1 transmission to T-cells (Saeland et 
al., 2009). Cytokines are known to play a role in immune-modulation and immune-protection 
of breast milk (Chirico et al., 2008). 
 
1.12 HIV-1 in South Africa 
 
Human immunodeficiency virus type 1 (HIV-1) is an enveloped virus that was first isolated 
from a patient in Paris in 1983. This virus infects primarily human CD4-positive T cells and 
macrophages (Sakomoto et al., 2003). HIV gains entry into host cells via interaction of the 
viral envelope protein gp120 with at least one co-receptor expressed on the surface of the host 
cell membrane (Jenkinson et al., 2003). Post viral exposure, HIV-1 infection is charecterised 
by an early period of antigenemia in which HIV-1 antigens (Ag) are detectable in the blood. 
P24 antigen is one of the components of the virus which forms the major internal structural 
protein of HIV-1. HIV p24 antigen tests employ ELISA technology with modifications to 
detect the antigen. HIV viral tropism is determined by the gp120 expressed on the virus and 
the chemokine receptors present on the cells. Macrophage tropic (M-tropic) HIV-1 strains 
tend to use CCR5 while the T lymphocytic–tropic (T-tropic) HIV-1 strains utilize CXCR4 as 
their co-receptors. The Dual tropic strains utilize both CCR5 and CXCR4 (Hong et al., 1999). 
When gp120 binds with CD4 and the appropriate co-receptor, conformational change and 
unmasking of a second viral envelope called gp41 occurs. The interactions of gp41 with the 
host cell membrane, results in the fusion of the viral envelope with the cell. This allows for 
the transfer of viral genetic information into the host cell and continuation of viral replication 
(Jenkinson et al., 2003). Infection with HIV- 1 results in progressive deterioration of the 
immune system due to qualitative and quantitative defects of CD4
+
 T-lymphocytes (Sakomoto 
et al., 2003). 
 
South Africa is reported to have more human immunodeficiency virus infected people than in 
any other country in the world, with a national HIV prevalence of 11.4% (Jaspan et al., 2006). 
The first national population-based HIV survey was conducted in 2002 and showed that 9.3% 















likely to be infected than males (Jaspan et al., 2005). HIV-1 subtype C is the predominant 
HIV-1 genotype in Southern Africa and is rapidly spreading throughout the world (Ndung’u 
et al., 2006) and accounts for approximately 50% of pediatric HIV-1 infections (Zhang et al., 
2006). 
 
1.13 Breast-feeding and HIV transmission 
 
Women of child bearing age constitute nearly half of the 30 million adults currently living 
with HIV/AIDS in the world (Dabis et al., 2000). According to a report by UNAIDS, 
approximately 1 million women give birth each year in South Africa, with more than 250 000 
of these infants being born to HIV-infected mothers (Jaspan et al., 2005). 
Breast-feeding maintains the maternal-fetal immunologic link after birth which may favour 
the immuno-competence transmission from the mother to her infant. It is also considered an 
important contributory factor to the neonatal immune defence system which is not well 
developed at birth (Chirico et al., 2008). Breast-feeding has been shown to lower the 
incidence of other infectious diseases during the first year of life. A large number of studies 
have shown that breast-fed infants have a lower incidence of gastrointestinal and respiratory 
system infections than do bottle-fed infants (Peterson et al., 1998). The with-holding of breast 
milk can have serious consequences for infants living in areas of the world where enteric 
disease is endemic, for both HIV-infected and HIV-uninfected infants (Newburg et al., 1995). 
 
Human breast milk is rich in mucin. However, mother-to-child transmission of HIV-1 through 
breast feeding accounts for the majority of HIV-1 infections among infants as high as 40% 
(Habte et al., 2008 and Schroten et al., 1992). Proteins present in milk such as lactoferrin, 
lysozyme and secretory leukocyte protease inhibitor have been shown to possess anti-HIV 
properties (Naarding et al., 2005). 
 
1.14 Questions and Objectives of the study 
Human breast milk is rich in components, such as mucin, that have been reported to protect 
against pathogens and viruses (Habte et al., 2007). The question is that despite all these 
protective components in breast milk, HIV-1 transmission from mother to child is still a huge 
risk? The biological objectives of the study are to isolate, purify, characterise and determine 















MUC1 and MUC4, in HIV positive patients compared with those who are not infected. This 
study will also test the effect that heat might have on breast milk which we think can release 




















































This study was approved by the University of Cape Town Health Sciences Faculty Research 




Guanidinium chloride (GuHCl), agarose, bovine serum albumin (BSA) and caesium chloride 
(CsCl) were obtained from the Sigma Company, St Louis, USA. Dialysis tubing and pure 
nitrocellulose membranes (0.22um) were purchased from Argon Laboratory Services, RSA. 
ULTRA CLEAR
TM
 centrifuge tubes (16 x 76 mm) were supplied by Beckman International. 
Ammonium persulphate (AMPS), Folin-ciocalteu phenol reagent, acrylamide, N,N’-
methylenebisacrylamide (Bis), N-ethylmaleimide (NEM), sodium metabisulphite, sodium 
dodecyl sulphate (SDS), periodic acid and 2-mercaptoethanol were supplied by the British 
Drug House, Dorset, UK. Phenylmethylsulfonylfluoride (PMSF), N,N,N,N’-
tetramethylethylenediamine (TEMED), Coomassie Brilliant Blue-250, sodium carbonate 
anhydrous, disodium hydrogen orthophosphate anhydrous and sodium dihydrogen 
orthophosphate were from SAARCHEM (Merck). Monoclonal mouse anti-MUC1 antibody 
was from Novocastra (Newcastle, UK). Monoclonal mouse anti-MUC4 was from Santa-Cruz. 
The HRPO linked rabbit anti-mouse secondary antibody was from Dako-Cytomation. The 
syngene G: Box was from Vacutech. The 293T cell line was from the American Type culture 
collection, catalogue No CRL 11268. TZM-bl cell lines were from the NIH AIDS Research 
and Reference reagent program (catalogue No 8129). Alcian Blue was from Sigma-Aldrich 
Corp, ST Louis, MO). The AG50WX8 cation-exchange resins were from Bio-Rad. The 100 
kDa molecular weight cut-off spin filters were from Millipore, Bedford, MA. The negative 
ion LC-ESI-MS and MS/MS (ion trap LCQ DECA system) was from Thermo Electron Corp., 
Waltham, MA). HyperCarb porous graphitized carbon columns (5 μm HyperCarb, 0.32 × 150 
mm) were from Thermo Hypersil-Keystone, Bellefonte, PA. Surveyor auto-sampler was from 
Thermo-Finnigan, San Jose, CA. The high-pressure liquid chromatography column for amino 















glutamine, sodium pyruvate, glucose and pyridoxine (catalogue No 41966029); fetal bovine 
serum (FBS) (catalogue No 10106-169); Sterile trypsin-EDTA (catalogue No 25200-056); 
sterile PBS (catalogue No 10010015) was from Gibco BRL life technologies. DEAE dextran, 
hydrochloride (catalogue No D9885) were from Sigma. 
 
2.3. Sample collection 
 
2.3.1. Collection of breast milk from HIV positive and HIV negative patients 
 
Human breast milk samples were collected from forty HIV negative and thirty HIV positive, 
lactating mothers from the post-natal and neonatal wards at Groote Schuur Hospital (Cape 
Town, South Africa). The milk samples were collected into 5ml 6M guanidinium chloride 
(GuHCl), 1mM phenylmethylsulfonylfluoride (PMSF) and 10mM ethylenediaminetetra-acetic 
acid (EDTA) at a ratio of approximately 1:5, immediately frozen at -20
o
C and stored. In 
preparation for the inhibition assay, milk was thawed, dialysed overnight at 4
o
C against three 
changes of distilled water and then freeze-dried. 
 
2.4 Heat treatment of milk 
 
Crude milk samples were heat treated in order to determine the effect of heat on the milk. 
Crude milk (1ml) samples from each individual were aliquoted, dialysed and freeze dried 
before reconstituting with 10% DMEM and then heating at 80
o
C for 10 min in preparation for 
the neutralization assay.  
 
2.5 Preparation of milk fat globule membrane 
 
Milk fat globule membrane was prepared according to the method of Schroten et al (1992). 
Frozen milk samples were thawed at room temperature in the presence of 1mM PMSF, 10mM 
EDTA and 6M GuHCl. Milk was defatted by centrifugation at 3000g for 1 hour at 4
o
C. The 
cream at the top of the tube appeared as a yellow fraction which was removed and 
resuspended in 0.2M sodium chloride (NaCl), 0.02% sodium azide (NaN3) containing 10mM 
EDTA and then kept at 4
o
C for 1 hour. This suspension was placed on a shaker at room 
temperature overnight until butter formed. The butter mixture was then incubated at 40
o
C in a 















as a yellow pellet by ultracentrifugation for 30 min at 35, 000 g at 4
o
C. The yellow membrane 
pellet was resuspended in 0.2M NaCl, 0.02% NaN3 containing 10mM EDTA, then subjected 
to homogenization, using a Junkel Ultra-Turrax for 1 min at 9500 rev at room temperature to 
disaggregate it and increase its solubility. Insoluble materials were removed by centrifugation 




2.6 Sepharose CL-4B gel filtration 
 
Sepharose CL-4B gel filtration was used to separate MFGM material as peaks I and II. The 
method is used to separate the biological material according to size, between a continuous size 
phase and the smaller interior gel pore size (Brooks et al., 2000). The column was 
equilibrated and samples eluted using 0.2M NaCl, 0.02% NaN3 containing a cocktail of 
protease inhibitors. Following periodic acid Schiff (PAS) and protein A(280) assays, the void 
and included volume fractions were pooled separately, dialysed against three changes of 
distilled water overnight at 4
o
C and then freeze dried. 
 
2.7 Analytical determination 
 
2.7.1 Lowry Assay 
 
The protein assay was done to determine the amount of total protein present in the MFGM 
samples. Protein was estimated according to the method of Lowry et al (1951). The two basic 
steps for this method are; the formation of a copper ion complex with amide bonds, resulting 
in reduced copper in alkaline solution and the reduction of Folin-Ciocalteu reagent 
(phosphomolybdate and phosphotungstate) by tyrosine and tryptophan residues. This 
reduction of Folin-Ciocalteu reagent results in a blue colour formation detected at 690nm. 
Despite its variation in colour with respect to different proteins and interference by different 
laboratory chemicals such as detergents, carbohydrates, glycerol, EDTA, caesium chloride, 
mercaptoethanol and Triton X-100, it is more sensitive than UV detection of proteins at 
280nm. For this study, 10ul of MFGM sample, 10μl NaOH and 200ul solution containing 
(anhydrous sodium carbonate, copper sulphate and sodium tartrate) was incubated for 10 min 
at 25
o
C before the addition of 20μl Folins solution. The mixture was then incubated for a 
further 30 min at 25
o















curve with bovine serum albumin of known concentration was included in every assay to 
determine the concentration of protein in the crude milk samples. 
  
2.7.2 Total protein concentration determination in crude milk (Bradford assay) 
 
Protein quantification was also performed using the modified Bradford assay (Bradford, 
1976). This method involves the binding of Coomassie Brilliant Blue G-250 dye to proteins. 
The dye exists in three forms: cationic (red), neutral (green), and ionic (blue). Under acidic 
conditions, the dye is predominantly in the doubly protonated red cationic form. However, 
when the dye binds to protein, it is converted to a stable un-protonated blue form, detected at 
595nm in the assay using a spectrophotometer or microtitre plate reader. BSA was used as the 
standard to generate the calibration curve.  Using the microtitre plate, 5μl crude milk sample 
was added to the 250μl dye reagent, then incubated at room temperature and read after 5 min 
but not longer than 1 hour. The absorbance was measured at a wavelength of 595nm. 
 
2.7.3 PAS Assay 
 
Glycoproteins in mucins were estimated by the Periodic Acid Schiff (PAS) procedure of 
Mantle and Allen (1978). This method involves oxidation of the hydroxyl (-OH) group to 
aldehyde (-CHO) by periodic acid. Subsequently, the aldehyde group reacts with Schiff 
reagent to form a red-purple product. In the case of the mucins the periodic acid/Schiff 
reagent stains the vicinal diol groups of the peripheral sugars and sialic acids (Thornton et al., 
1996).  Briefly, 20μl sample was incubated at 37
o
C for 1 hour with periodic acid solution, and 
then 200μl decolorized Schiff reagent was added before incubating for 30 mins at room 
temperature. Absorbance was read at 555nm on a microtitre plate reader. 
 
2.8 Dialysis of samples 
 
Prior to PAS, Lowry, SDS-PAGE and Western blotting analysis, GuHCl and caesium 
chloride (CsCl) were removed from the samples by dialysis as they interfere with these 
assays. Dialysis is based on the principle of osmosis and concentrates proteins in their native 
state. However, substantial loss of mucins may occur during dialysis due to their sticky 















distilled water in the presence of EDTA and sodium carbonate. Samples were dialysed 




Freeze-drying was done to remove water from the samples in order to determine the total 
weight of the dry sample. Prior to freeze-drying, samples were placed into plastic containers 
with holes in their lids and frozen at -80°C overnight. Thereafter, samples were placed into 
suitable vacuum flasks for freeze drying. This was done by using the Christ ALPHA 1-5 
freeze drier from Laboratory and Scientific Company. 
   
2.10 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
SDS-PAGE was done in order to determine the presence and purity of the mucins and to 
determine their size. Breast milk mucins were prepared in reducing gel loading buffer 
containing 2% SDS, 10% glycerol, 0.01% bromophenol blue and 5% mercaptoethanol and 
placed in boiling water for 1 min prior to loading. Electrophoresis was performed according to 
the method of Laemmli (1970) in a 10% (w/v) running gel and a 4% (w/v) stacking gel using 
the Hoeffer Mighty small mini-electrophoresis system. Briefly, the running gel was made as 
follows: 3.67 ml 30% Bis/Acrylamide, 3.90 ml 0.1% SDS, 3.60 ml running buffer, 100ul 
ammonium persulphate (AMPS), 5ul N,N,N’,N’-Tetramethylethylendiamine (TEMED). The 
running gel was poured between two gel plates; water was added on top to prevent the gel 
from drying. The gel was left to set. The stacking/spacer gel was made as follows: 0.5ml 30% 
Bis/Acrylamide, 2.8ml spacer buffer, 73μl AMPS and 5 ml TEMED. The water was poured 
off the running gel and the spacer gel was poured on the set running gel.   A comb was 
inserted into the gel to make wells until the stacking gel had set. The gel was run at 
20mAmps, until the bromophenol blue had reached the bottom of the gel. The gel was stained 
with PAS for glycoproteins or Coomassie Brilliant Blue R-250 for proteins. 
 
2.11 Dot Blotting  
 
Dot blotted samples were used for beta elimination analysis of O-linked oligosaccharides as 















A Bio-rad blotting apparatus was used for the dot blots for beta elimination analysis and the 
Schleicher and Schuell Minifold II slot/dot blot apparatus was used for the dot blots for 
glycoform determination. The PVDF (beta elimination analysis) and nitrocellulose 
(densitometric scanning of the mucins from PAS) membranes was soaked in methanol for 2 
min and then into distilled water (dH2O) for another 2 min. A precut filter was also soaked in 
dH2O for 2 min. The wet filter paper was placed on the gasket support plate before placing the 
wet membrane on top of the filter. The dot blot apparatus was assembled according to the 
manufacturer’s instructions. 
Using a narrow-mouth pipette tip, 40μl of sample was loaded onto the nitrocellulose 
membrane at the center of the grid. The sample was blotted onto the nitrocellulose membrane 
using a vacuum pump attached to the dot blot apparatus. The dot blots were either stained 
with Alcian blue (or direct blue) for beta elimination analysis or with PAS for densitometric 
scanning of the mucins. 
 
2.12 Periodic acid Schiff gel staining 
 
The SDS-PAGE gels were stained with PAS to determine the presence and size of the mucins. 
The gels were stained according to the method of Dubray and Bezard (1982). Briefly, the 
SDS-PAGE gels were placed for staining in 50% ethanol for 30 mins, and then washed in 
distilled water for 10 min. The gel was placed in 1% periodic acid made up in 3% acetic acid 
for 30 mins, then washed in distilled water for 30 mins or overnight. The gel was placed in 
0.1% sodium metabisulphite in 10mM hydrochloric acid for 2 x 10 mins, then in Schiff 
reagent in the dark for 60 mins. The gel was then placed in 0.1% sodium metabisulphite in 
10mM hydrochloric acid for 60 mins in the dark and then photographed. 
 
2.13 Coomassie Brilliant Blue R-250 gel staining  
 
SDS-PAGE gels were stained with Coomassie Brilliant Blue R-250 for the detection of 
proteins. In this method the dye-anion is electrostatically attached to the NH3
+
 group of the 
protein in a slightly acidic solution. This dye-protein bond is fixed but can be fully reversed 
by changing pH (Fazekas de St et al., 1963). In this present study gels were stained overnight 
with 0.1% Coomassie Brilliant Blue R-250 in 30% methanol and 10% acetic acid and 
destained in 20% methanol and 10% acetic acid until the required bands were clearly visible. 















2.14 Agarose gel electrophoresis 
 
In this method gels are prepared by dissolving agarose in warm electrophoresis buffer to give 
a specific concentration (0.7%) of agarose. Once it has solidified, the agarose gel forms a 
matrix, the density of which depends on the concentration of the agarose. During 
electrophoresis, mucins, which are negatively charged at a neutral pH, migrate towards the 
anode. The mobility of the proteins is influenced by the agarose concentration and sample size 
with the smallest molecules migrating the longest distance (Boyer, 1993). The mucins were 
added to the sample loading buffer containing 40% glycerol, 0.01% bromophenol blue and 
5% mercaptoethanol in 1x Tris-acetate buffer and boiled for 2 min prior to loading onto the 
gel. Electrophoresis was carried out in a 0.7% (w/v) agarose gel prepared in running buffer 
containing 40mM Tris-acetate buffer, 1mM EDTA and 0.1% SDS pH 8.0. The agarose was 
boiled in a microwave until it completely dissolved and cooled down to approximately 50°C 
before pouring into the Bio-Rad DNA sub-cell gel apparatus. Upon polymerization the 
apparatus was filled with running buffer (TAE containing 0.1% w/v SDS) and electrophoresis 
was performed at 65 V, for 3 hours at room temperature. 
 
2.15 Western blotting analysis 
 
The identity of the mucins was performed by western blotting. This method involves agarose 
gel separation and vacuum transfer of samples to nitrocellulose membrane for their 
recognition by antibodies (Hughes et al., 1988). Subsequent to blocking of the free binding 
sites on the membrane with non-fat milk powder, antigens are accessible to bind with their 
corresponding primary and secondary antibodies. The secondary antibodies which are specific 
to the primary antibodies are labeled with enzymes such as horse radish peroxidase, which 
react with substrates to form an insoluble coloured product. 
Equal amounts of mucins (400μg) were resolved separately on 0.7% agarose gels. After 
agarose gel electrophoresis, the mucins were transferred to a nitrocellulose membrane 
(Nitrocellulose, 0.22 Micron) using a vacuum-blotting unit at 40mBars for 1 hour. The 
transfer buffer used was 4x SSC. After vacuum-blotting, non-specific binding was blocked by 
incubating the membranes for 30 min in 5% (w/v) low-fat milk powder in Tris-buffered saline 
















The membranes were then washed with TBST for 3 x 5 min before incubating overnight with 
1:100 diluted mouse anti-MUC1 NCL monoclonal antibody (specific against the carbohydrate 
epitope of the human MUC-1 glycoprotein) diluted in 5% (w/v) low fat milk powder in TBST 
or with 1:200 diluted human MUC4-specific 1G8 monoclonal antibody (it recognizes an 
epitope in the central portion of the ASGP-2 between the 53aa at the N- terminus and the trans-
membrane domain). The membranes were washed for 3 x 5 min with TBST and incubated for 
30 min with HRPO linked rabbit anti-mouse secondary antibody diluted in 5% (w/v) low-fat 
milk powder in TBST at 1: 1000 concentrations. After another TBST wash (3 x 5 min), the 
membranes were treated with LumiGLO Reserve Chemiluminescent Substrate for 1 min and 
detected using the syngene–G: Box. 
 
2.16 HPLC Ion-Exchange Chromatography  
 
This study was performed in the laboratory of  Professor David Thornton in the department of 
Biochemistry and Molecular Biology, University of Manchester, United Kingdom under the 
kind auspices of the South African National Research Foundation. The high-Mr glycopeptides 
were chromatographed on a Pharmacia Mono Q HR 5/5 ion-exchange column using a 2150 
LKB titanium-head pump connected to a 2152 LKB controller and a 2040-203 LKB mixing 
valve according to the method described by Thornton et al., (1991). Before chromatography, 
freeze dried samples of the MFGM-I (6mg) were resuspended into 6M urea. Because the 
samples were still poly-dispersed, samples were further resuspended into 4M urea. Gradients 
were formed at the low-pressure side and samples were loaded with a Pharmacia V-7 injector. 
The column was eluted at a flow rate of 0.5 ml/min, first isocratically for 10 min with 10 mM-
piperazine/perchlorate buffer, pH 5.0 (buffer A), then with a linear gradient (60 min) to 
0.25M-lithium perchlorate/10mM-piperazine/perchlorate buffer, pH 5.0 (buffer B). Fractions 
(0.5 ml) were analyzed for neutral sugars using a PAS assay (Mantle & Allen, 1978).  
 
2.17 Amino acid analysis 
 
The amino acid content of the breast milk mucins was determined by amino acid analysis. 
This involves four basic steps namely: the hydrolysis of the protein to its individual amino 
acid content, labelling of amino acid with a detectable marker, high pressure liquid 
chromatography (HPLC) separation of mucins and data interpretation. The amino acid content 















of Klapper (1982). The samples were vacuum-dried and placed in a hydrolysis vessel 
containing some constantly boiling hydrochloric acid (HCl) and 1% (v/v) phenol. The vessel 
was purged with nitrogen gas and sealed under vacuum. The samples were then hydrolyzed in 
the gas phase at 110°C for 24 hours. Following hydrolysis, the vessel tip was cooled and 
vacuum dried to remove the residual HCl. The dried samples were re-dissolved in citrate 
buffer pH 2.2 and injected into a high-pressure liquid chromatography column packed with a 
cation exchange resin (sulfonated polystyrene cross-linked with divinylbenzene) and eluted 
with a series of buffers ranging from a low (0.25M trisodium citrate, pH 3.05) to high (0.25M 
sodium nitrate, pH 9.5) pH. Detection was carried out using post-column derivatization with 
o-phthalaldehyde, a fluorescent reagent that reacts with all the amino acids except proline. For 
proline detection, the samples were treated with sodium hypochlorite ahead of post column 
derivatization with OPA. The relative ratios of the individual amino acids for each sample 
were determined and compared. 
 
2.18 Growing TMZ-bl cells from frozen stocks 
 
TZM-bl cells were used in the pseudoviral neutralisation assay. Frozen TZM-bl cells were 
thawed quickly by placing the tube in a 37
o
C water bath. Cells were removed from the 
cryotube with a 1ml pipette and placed in a 15ml sterile tube. The DMSO (toxic) in the cells 
was diluted out by adding 9ml culture media drop by drop to prevent the production of stress 
protein due to shock, and gentle swirling often. The 15ml tube was centrifuged at room 
temperature 1200rpm for 7 min.  The supernatant was removed by aspiration. The pellet was 
re-suspended with 12ml culture media and placed into labelled plates (first re-suspend with 
5ml media before adding the rest to make up 12ml). The plates were incubated at 37
o
C in a 
CO2 incubator. 
 
2.19 Maintenance of TZM-bl cell lines  
 
TZM-bl cells were cultured with 5% DMEM media (containing DMEM, FBS, HEPES and 
gentamycin, NEAE) until the cells were 60-80% confluent. The plates were examined under 
the microscope to check that the TZM-bl cells were approximately 80-90% confluent and that 
there was no fungal or microbial contamination. The media was removed by aspiration and 
discarded. PBS (5ml) was added on to the plate and the plate was “washed” by gently 















discarded. Trypsin-EDTA (1ml) was added to the plate allowing the trypsin to cover the entire 
surface of the plate to which the cells were attached. The cells were allowed to incubate at 
37°C in CO2 incubator for 4 min. Cells were detached from the surface by tapping the plate 
gently before examining under the microscope.  Culture media (5ml) was added into the plate 
to neutralise the trypsin. The suspension was centrifuged (1200 rpm for 5min) to pellet the 
cells. The supernatant was removed by aspiration and cells were re-suspended in 5ml media. 
The re-suspended cells (1/3 volume) were added to a fresh plate containing 10ml culture 
media. The plate was placed in 37°C incubator with CO2. 
 
2.20 Production and titration of HIV-1 Env pseudovirus 
 
Stocks of single-round infection HIV-1 Env pseudovirus were produced as previously 
described (Montefiori, 2005) by co-transfecting 293T/17 cells (3 x 10
6
 cells per T75 flask) 
with 4μg of an HIV-1 rev/env expression plasmid and 8μg of an env-deficient HIV-1 
backbone plasmid (pSG3 Env) using FuGENE transfection reagent. Pseudovirus-containing 
supernatant was harvested 48 hours following transfection and clarified by filtration through a 
0.45 micron filter. Single-use aliquots (1.0ml) were stored at -80°C. The 50% tissue culture 
infectious dose (TCID50) for each pseudovirus preparation was determined by infection of 

















































Infection does not occur with an inhibitor
 
Figure 2.1 Sequential events in detection neutraliszation of Env-pseudotyped viruses in TZM-bl 



















2.21 HIV pseudovirus  neutralization assay using a luciferase reporter gene in TZM-
bl cells 
 
Virus neutralization was measured using a luciferase based assay in TZM-bl cells as 
previously described by Montefiori, (2005) with modification. This assay measures the 
reduction in luciferase reporter gene expression in TZM-bl cells following a single round of 
virus infection. Briefly, TZM-bl cells were added into a 96-well flat bottom microtitre plate (1 
x 10
4
/well in a 50μl volume) in 10% DMEM growth medium containing DEAE-dextran at a 
final concentration of 7.5μg/ml. Assay controls included replicate wells of TZM-bl cells alone 
(cell control) and TZM-bl cells with virus (virus control). The TZM-bl cells were allowed to 
incubate for 26 hours before mucin samples and viruses were added. On a separate 96-well 
flat bottom microtitre plate, 3-fold serial dilutions of milk mucin samples (starting at 
500μg/ml) were performed in duplicate in 10% DMEM growth medium (100 μl/ well). An 
amount of diluted Du422.1 pseudovirus which would yield  approximately 50000 RLU 
equivalent   (50x dilution yields 50 000 RLU, viral dilution in each well is 1:4. dilution for 
virus and media that was added was1:12.5) was added to each well in a volume of 50μl, and 
the plates were incubated for 1 h at 37°C.  Then 150μl mucin and viral suspension was 
transferred into the 96-well flat bottom plate containing cells.  
 
Following 48 hour incubation at 37°C, 100μl culture medium was removed from each well 
and 100μl of Bright-Glo luciferase reagent was added. The cells were allowed to lyse for 2 
min in the dark, and then 100μl of the cell lysate was transferred to a 96-well black solid 
plate, and luminescence was measured using a Victor 3 luminometer. The 50% inhibitory 
dose (ID50) titre was calculated as the mucin dilution that caused a 50% reduction in relative 
luminescence units (RLU) compared to the level in the virus control wells after subtraction of 
cell control RLU. All data were analyzed using  Graph Pad prism version 5.0 (Graph Pad, La 
Jolla, USA) dose response inhibition. 
 
2.22 MTT colorimetric assay 
 
The rate of replication of each of the TZM-bl cell lines in the presence of human breast milk 
mucins was determined by lympho-proliferative assay using MTT dye [3-(4,5-dimethyl 
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide], according to the method described by 















modifications. The assay was carried out as follows. TZM-bl cells were harvested from a 
plate, pelleted by centrifugation (1000rpm for 5min) and resuspended in approximately 5ml of 
fresh growth medium (containing DMEM, FBS, HEPES and gentamycin). The viable cells 
were counted by trypan blue dye (1:4 10ul cells: 30ul trypan blue) exclusion test and the cell 
count was adjusted to 1×10
5
 cells/ml. In plate 1, a suspension of 50μl/well (1×10
4
) cells in 
media was plated with 50μl growth media into each well. To serve as blank, all wells in 
column 1 (from A-H) were plated with only media. Column 2 wells (from A-H) were plated 
with media and cells to serve as the cell control. Other wells in column 3 had media, cells and 
solubilization reagent in order to serve as an example to show cell death. The cells were 
allowed to incubate for 26 hours before adding breast milk mucins. In a separate 96 well plate 
2, each crude milk or purified milk mucin sample was done in triplicate. The initial volume of 
the samples was 250ul with a starting concentration of 250μg/ml in DMEM media. The 
samples were 2 fold serially diluted down in 125ul media. After the samples were diluted, 
100μl of each diluted mixture from plate 2 was transferred to plate 1 which contained 50μl 
cells and 50μl growth media to make a final volume of 200μl. The blank (200μl GM), cell 
control (150μl GM, 50μl cells) and cells with solubilization agent (140μl GM, 50μl cells, 10μl 
solubilization agent) did not have mucins, but were each adjusted to have a final volume of 
200μl. The plate was incubated after adding mucins at 37°C in 5% CO2 for 44 hours before 
adding 20μl MTT dye (5 mg/ml of phosphate buffered saline (pH 7.2) stock, Sigma) to each 
well. The plate was incubated for another 4 hours before discarding 100μl from each well and 
then adding 100μl of dimethylsulfoxide (DMSO, Sigma) to all the wells to dissolve the 
formazan crystals . The plate was incubated overnight before reading the optical density (OD) 
at a test wave length of 490 nm and reference wavelength of 650 nm on UVmax kinetic 
microplate reader (Molecular Devices) replication index (RI) was calculated from the formula 































This chapter describes the purification of milk mucins from the crude milk sample. The milk 
fat globule membrane (MFGM) was prepared from crude milk before the mucins could be 
isolated from it for characterization purposes. The MFGM was prepared by defatting the 
breast milk by centrifugation at 3 000g for 1 hour at 4
o
C. Milk mucins were isolated by 
Sepharose CL-4B gel filtration and purified by isopycnic density gradient centrifugation in 
3.5M caesium chloride and 4M guanidinium chloride. The presence and the purity of milk 
mucins in the breast milk were assessed by SDS-PAGE gels which were stained for 
carbohydrate with PAS and for protein with Coomassie Blue stain R-250. The identity of 




3.2.1 The SDS-PAGE analysis of crude MFGM material  
 
The SDS-PAGE analysis of the prepared milk fat globule membrane (non-purified) was done 
in order to confirm the presence of mucins.  The MFGM samples (50μl) from HIV positive 
and HIV negative patients were prepared in reducing gel loading buffer and subjected to 10% 
SDS-PAGE and the gels were stained with PAS, a carbohydrate stain and Coomassie Brilliant 
Blue, which stains for protein. The SDS-PAGE gels from the HIV positive MFGM (Figures 
3.1 A) and HIV negative MFGM (Figures 3.1 B) showed the presence of high molecular 
weight PAS positive bands which were found on top of the stacking gel as well as some that 
have entered the running gel. The mucins that have entered the running gels for both groups 
seem to vary in intensity and appear as rather broad bands or even smears in the region of 
molecular weight (Mr ~ 220kDa, and spread as far down as 100kDa). The MFGM from the 
HIV positive group (Figures 3.1 A) seem to have more intense staining than the MFGM from 
the HIV negative (Figures 3.1 B), although there is an inter-individual variation from sample-















positive group (Figure 3.1A lanes 2-9), the most prominent bands in this region for the HIV 
negative group are in lanes 2 and 8 (Figure 3.1B), with bands in the other lanes being of lesser 
intensity (Figure 3.1A, lanes 3-7).  The Coomassie Brilliant Blue stained gel (Figure 3.2) 
shows that the MFGM material from both groups has other contaminant proteins other than 
the mucins of interest. However there is an inter-individual variation of size and smear-like 
material in the region of Mr ~ 100-220kDa, together with a distinct and separate band below 
this smear at roughly 50 kDa in some samples (Figure 3.2 lanes 4-7 and 9-12). 
 
3.2.2 Sepharose CL-4B gel filtration of the crude milk fat globule membrane material 
 
Sepharose CL-4B gel filtration was used for the separation of MFGM-I from MFGM-II. 
Twenty (20) ml of the MFGM material was chromatographed on a Sepharose CL-4B column 
(height 20cm, diameter 2cm and bed volume 100ml) and eluted with 0.2M NaCl, 0.02% NaN3 
at a flow rate of 2 min/tube. Figure 3.3 shows a profile of a representative sample from each 
group. The elution profiles for the HIV positive group (Figure 3.3A) and HIV negative group 
(Figure 3.3B) show that the MFGM material elutes as two peaks in both groups. The first 
peak eluted in the void volume (Vo) (MFGM-I) whilst the second peak eluted in the included 
volume (Vi) (MFGM-II).  The HIV positive group (Figure 3.3A) had two large distinct peaks 
while the HIV negative group showed one small peak and one large peak. The MFGM-I and 
MFGM-II peaks from the HIV positive group showed more mucin which was assayed by 
PAS than the peaks from the HIV negative group as shown on the elution profiles. There was 
a background of protein (Bradford assay 490nm) in both groups.  
 
The difference in the staining intensity of mucins between the two groups was confirmed by 
separating the freeze dried MFGM-I and MFGM-II under the peaks in both groups on a 10% 
SDS-PAGE after being dissolved in sample application buffer containing 0.2M 2-
mercaptoethanol and staining with PAS for carbohydrates. The PAS staining was more 
intense in the HIV positive (Figure 3.4A, lanes 2-9) than in the HIV negative group (Figure 
3.4B, lanes 2-7) for equal loading, in a region of about Mr ~ 170 kDa. The MFGM-I material 
from both groups (Figure 3.4) shows more intensely stained mucins than the MFGM-II 
material. In both groups, MFGM-I has less contaminant proteins than MFGM-II as shown in 
Figure 3.5, stained for protein by Coomassie Brilliant Blue. Again there is more intense 
















3.2.3 Western blotting analysis of semi-crude (post gel filtration) MFGM-I and 
MFGM-II material 
 
Western blotting analysis was done in order to confirm the identity of the mucins in the 
MFGM-I and MFGM-II samples. Freeze dried material from MFGM-I (400µg) and MFGM-
II (400µg) from the HIV positive and HIV negative groups dissolved in sample application 
buffer containing 0.2M 2-mercaptoethanol were separated using 0.7% agarose gel 
electrophoresis and then transferred to a nitrocellulose membrane. The membranes were 
probed with mouse anti-MUC1 monoclonal antibody (Figure 3.6) and mouse anti-MUC4 
monoclonal antibody (Figure 3.7).  
 
The results showed that the MUC1 and MUC4 were detected in both groups. Figure 3.6; lane 
1 is a bronchial lavage which was found to be positive for MUC1. Figure 3.6; lane 2 is a 
cervical mucin which is a positive control. Intense staining was seen for the Vo (MFGM-I) 
material for MUC1 in the HIV positive group (Figure 3.6 lanes 3, 5, 7) than the Vi (MFGM-
II) material (Figure 3.6 lanes 4, 6, 8). Interestingly, the Vi material from one patient (Figure 
3.6 lanes 10) was as intense but not as widely smeared as that from the Vo (MFGM-I) group 
(Figure 3.6 lanes 9). There was obvious inter-individual variation in both the HIV positive 
and the HIV negative groups for both peaks. The HIV negative group had far less material in 
both the Vo and Vi   peaks with the Vi peaks hardly having material that was detectable.  
 
MUC4 was also detected in both the HIV positive and the HIV negative group. Figure 3.7; 
lane 1 is a bronchial lavage which is positive for MUC4. Figure 3.7; lane 2 is a cervical mucin 
which is a positive control. There seemed to be more MUC4 in the samples from the HIV 
positive group (Figure 3.7; lanes 3-10) than the HIV negative group (Figure 3.7; lanes 11-18), 
and in both groups, the MFGM-I material (Figure 3.7; lanes 3, 5, 7, 9, 11, 13, 15, 17) seemed 
to have more MUC4 than the MFGM-II material (Figure 3.7; lanes 4, 6, 8, 10, 12, 14, 16, 18). 
There seemed to be no detectable MUC4 in the MFGM-II material in the HIV negative group 



















3.2.4 Purification of MFGM-I material from the Sepharose 4B gel filtration column by 
caesium chloride isopycnic density gradient centrifugation  
 
The MFGM-I from the HIV positive and HIV negative groups had more mucins and less 
contaminant proteins and nucleic acid in comparison to the MFGM-II as shown on the gels 
and Western blots. The MFGM-I from both groups were further purified by caesium chloride 
isopycnic density gradient centrifugation. Representative profiles of purification are shown in 
Figure 3.8A for the HIV positive group and Figure 3.8B for the HIV negative group. These 
profiles show a clear separation between proteins (Bradford 595nm) and the mucins which 
were assayed by PAS (555nm).  
 
In order to confirm purification, the purified MFGM-I samples from both groups were 
separated on 10% SDS-PAGE and stained with PAS and Coomassie Brilliant Blue R-250. 
Figure 3.9, lanes 2-5 shows the SDS-PAGE gel stained with PAS which shows that the 
mucins were present in both groups (lanes 2-3 from the HIV positive group and lanes 4-5 
from the HIV negative group, arrow at the beginning of the running gel). The SDS-PAGE gel 
stained with Coomassie Brilliant Blue R-250 (Figure 3.9, lanes 6-9) showed proteins detected 
in the same region. Figure 3.9, lanes 6-7 are HIV positive samples and lanes 8-9 are samples 
from the HIV negative group. 
 
3.2.5  Amino acid composition of the human breast milk mucins from the purified 
MFGM-I material 
 
The identity of the MFMG-I from the HIV positive and HIV negative groups was further 
confirmed by amino acid analysis. Serine, threonine and proline amounted to a mean of 
11.5%, 11.8% and 17.7% for the HIV positive (Table 3.1) and 11.2%, 11.0% and 14.8% for 
the HIV negative group mucins (Table 3.2). For the HIV positive group, the amount of serine 
threonine and proline added up to 41% of the MFGM-I, while they added up to 37% of the 






















The main objectives of this chapter were to isolate, purify and characterise mucins from the 
human breast milk of patients with and without HIV-1 infection. Crude breast milk samples 
were diluted with cold 6M guanidinium hydrochloride (GuHCl) buffer in a ratio of 1:5  
GuHCl : milk. The 6M GuHCl contained a cocktail of protease inhibitors such as EDTA, 
NEM and PMSF to prevent endogenous proteolysis (Carlstedt et al., 1983). EDTA chelates 
ions, PMSF is a serine proteinase inhibitor and NEM inhibits thiol proteinases (Carlstedt et 
al., 1983). 
 
The mucin apoprotein backbone has a glycosylated region of densely packed carbohydrate 
side chains which protects the protein core from proteolytic digestion and a naked non-
glycosylated part which is susceptible to proteolysis (Snary and Allen, 1971). Guanidinium 
hydrochloride is a strong chaotropic agent that denatures the non-covalent bonds of mucin and 
renders it in its primary state (Francis and Bradford, 1976). Potential destructive methods such 
as sonication and high speed homogenization were avoided for solubilization of milk mucus. 
 
The milk fat globule membrane was prepared from the cream fraction of the milk by defatting 
through centrifugation at 3000g for 1 hour at 4
o
C (Habte et al., 2008). The MFGM had to be 
processed as the mucins in human breast milk are of the trans-membrane type and are 
embedded within the milk fat globule membrane as shown in Figure 1.1. Sepharose CL-4B 
gel filtration separated the MFGM samples into two peaks, which were labelled MFGM-I and 
MFGM-II respectively. MFGM-I had the mucin rich fractions while the MFGM-II contained 
some mucin but more associated protein. The mucins in the MFGM-I and MFGM-II were 
identified by Western blotting analysis, which confirmed that MFGM-I had increased 
amounts of MUC1 and MUC4 in comparison to MFGM-II, in both the HIV positive and 
negative groups. The MFGM-I from both groups was further purified by caesium chloride 
isopycnic density gradient centrifugation. Amino acid analysis of the MGFM-1 material with 
its characteristically high serine, threonine and proline content confirmed its identity as mucin 
for both groups (Andersch-Björkman et al., 2007). However amounts of these amino acids 
were higher than those reported for mucins by Allen (1981) but comparable to those for 
















Before any further analysis could be performed, MFGM had to be prepared. This MFGM 
surrounds the lipid droplets in milk and it arises during a process in which intracellular lipid 
droplets are enveloped as they bud off from the apical membrane by apocrine secretion and 
are released into the milk. Mucin glycoproteins are the major constituents of these 
membranes. The presence of mucins in the MFGM samples were assayed by SDS-PAGE gels 
which were stained with PAS which stains the vicinal diol groups of the peripheral sugars and 
sialic acids (Thornton et al., 1996). The SDS-PAGE gel results of the crude MFGM material 
from the HIV positive group (Figure 3.1A) showed the presence of mucins on the top of the 
stacking gel with the molecular weight >220 kDa and others that have entered the running gel 
with the molecular weight of  >100 kDa but ≤ 220 kDa. The gel of MFGM samples from HIV 
negative group (Figure 3.1B)  also presented with similar findings with the mucins on the 
stacking gel with a molecular weight of >220kDa and others that have entered the running gel 
with a molecular weight of >100kDa but ≤ 220 kDa. Previous reports suggest that the bands 
in the stacking gel represent MUC4 (which was previously known as MUCX) and the lower 
molecular band, MUC1 (Newburg et al., 1990) is represented on the running gel. 
 
There is an obvious variation in the staining intensity behaviour of the mucins between the 
HIV positive and the HIV negative group. The HIV positive group shows more intense PAS 
staining on the SDS-PAGE than the HIV negative group. Inter-individual variation in 
intensity was also noted within samples of the same group suggesting that there was no clear 
cut difference in the electrophoretic behaviour of mucins for these for HIV positive or 
negative groups. In some cases, the HIV positive (Figure 3.1A, lanes 2, 5, 9) and the HIV 
negative group (Figure 3.1B, lanes 2, 8, 9) had several bands that were more intensely stained 
than others. The Coomassie Brilliant Blue stained gel (Figure 3.2) shows that the MFGM 
material from both groups have other contaminant proteins other than the mucins of interest in 
the region of Mr ~ 100-220kDa and a separate band below this smear at roughly 50 kDa in 
some samples 
 
After the presence of mucins was confirmed in the MFGM samples from both groups, the 
MFGM material was semi-purified by Sepharose CL-4B gel filtration. Two peaks for both the 
HIV positive (Figure 3.3A) and HIV negative (Figure 3.3B) groups were observed, and these 
were named MFGM-I and MFGM-II peaks. The peaks from the HIV positive group (Figure 
3.3A) were distinct, while the peaks from the HIV negative group (Figure 3.3B) had one 















of mucins were isolated in the MFGM-I peak as shown on the SDS-PAGE gels stained with 
PAS (Figure 3.4). The MFGM-II peaks for both groups had more contaminant protein and 
less mucin as shown by the Coomassie Brilliant Blue stained gels (Figure 3.5). 
 
The identity of the isolated mucins from the MFGM-I and MFGM-II was confirmed by 
Western blotting analysis to be MUC1 and MUC4. When separated on SDS-PAGE MUC1 is 
found on top of the running gel and it is smaller than MUC4 which is found on top of the 
stacking gel (Newburg et al., 1990). The detection of MUC1 mucins by Western blotting 
analysis in both groups (Figure 3.6) appears to have larger smears which run close to the top 
of the gel, whilst the MUC4 mucins (Figure 3.7) have smaller smears and running lower in 
the gel. This might appear as if MUC1 is larger than MUC4 but it is not the case. The 
explanation for this is that the mouse anti-MUC1 monoclonal antibody that was used is 
specific to the carbohydrate epitope of the human MUC-1 glycoprotein which is between 130-
300 kDa, while the human MUC4-specific 1G8 monoclonal antibody recognized an epitope in 
the central portion of the ASGP-2 between the 53aa at the N- terminus and the trans-
membrane domain which is 80 kDa. The antibody used for MUC4 was not specific to the 
larger 850 kDa membrane bound ASGP-1 subunit.  Both MUC1 and MUC4 were found in the 
MFGM-I in greater intensity (suggesting larger amounts) than for MGFM-II for both groups 
(Figure 3.6 and Figure 3.7). Despite their charge differences both MUC1 and MUC4 are large 
enough and share the same carbohydrate structure to elute in the excluded volume of the 
column (Patton et al., 1995). Trace amounts of MUC1 and MUC4 was also observed in the 
MFGM-II material of the HIV positive group but even more difficult to detect in the HIV 
negative samples. It is possible that the elution of these mucins in the included volume, 
though large enough to be excluded on Sepharose 4B gel filtration, were a result of small 
amounts of mucin sticking to the Sepharose material and resisting elution during column 
equilibration and washing with buffer in between sample loadings. In this study we were also 
unable to separate MUC1 from MUC4 to test their inhibitory potential against HIV-1 because 
of time constraints. However further work has been planned in this regard. 
 
Because almost all the mucin eluted as MFGM-I for both HIV positive and negative groups 
we considered it to be worthwhile to further purify the MGFM-I material. This purification 
was done successfully by isopycnic density gradient centrifugation in caesium chloride 
(Creeth and Denborough, 1970) and 4M guanidinium chloride (Carlstedt et al., 1983) which 















are shown in Figure 3.8A for HIV positive MFGM-I and Figure 3.8B for HIV negative 
MFGM-I. The fractions with the highest PAS peak were recovered between the densities 
1.32-1.41g/ml and 1.39-1.46g/ml respectively, and with the lowest protein levels. The extent 
of purification was monitored by SDS-PAGE analysis which showed an increased purity of 
the material, leaving large bands on the stacking and beginning of the running gels (Figure 
3.9).  
 
Mucin purity and identity was further confirmed by amino acid analysis of the MGFM-1 
material further purified by density gradient centrifugation. Although there was hardly a 
difference in the amount of serine, threonine and proline between the HIV positive and 
negative groups (41% and 37% respectively), the values obtained in this study for the 
percentage amounts of serine, threonine and proline per total amounts of amino acids are 
higher than previously reported (Allen, 1981). These amounts do vary and some researchers 
have reported higher percentages per total amino acids for serine, threonine and proline (Mall 
PhD thesis). This was due to the use of denaturing media in the extraction of mucins from 
crude mucus gels. It should also be noted that the studies on salivary mucin in HIV-AIDS in 
our laboratory, and the approach to their purification have, to our knowledge never been 
reported previously and the data here could well reflect the true amounts of serine, threonine 
and proline in MGFM-I material of saliva.     
 
Essentially, MFGM-I and MFGM-II were separated by Sepharose 4B and showed two bands 
on SDS-PAGE which were stained with PAS, and were identified as MUC1 and MUC4 on 





















Figure 3.1 10% SDS-PAGE analysis of the non-purified milk fat globule membranes stained with 
PAS. Milk fat globule membrane (MFGM) samples (50ul) were prepared in reducing gel loading buffer and 
subjected to 10% SDS-PAGE and the gels were stained with PAS for carbohydrates. Figure A illustrates the 
presence of mucin glycoproteins in MFGM from HIV positive samples. Lane 1: protein molecular weight 
marker. Lanes 2-9: HIV positive MFGM samples.  Figure B illustrates the mucins in MFGM from HIV negative 
samples. Lane 1: protein molecular weight marker. Lanes 2-9: HIV negative MFGM samples.  
 
                     
 
Figure 3.2 10% SDS-PAGE analysis of the non-purified milk fat globule membranes stained with 
Coomassie Brilliant Blue R-250. Samples of the milk fat globule membrane (50ul) were prepared in reducing gel 
loading buffer and separated on a 10% SDS-PAGE. The gel was stained for contaminant protein with Coomassie 
Brilliant Blue R-250. Lane 1: molecular weight marker. Lanes 2-7: HIV positive MFGM samples. Lanes 8-13:  













































Figure 3.3 Sepharose CL-4B gel filtration of the milk fat globule membrane (MFGM) material. An 
aliquot of MFGM (10ml) was chromatographed on a  Sepharose 4B column and eluted with 0.2M NaCl, 0.02% 
NaN3 containing protease inhibitors such as 10mM EDTA and 5 mM NEM, at the flow rate of 2 min/ tube at 
room temperature. The fractions were analysed for carbohydrates with PAS  at 555nm and protein with 
Bradford  assay at 490nm. Figures A and B are representative filtration profiles of MFGM from HIV positive 





































































































Figure 3.4 10% SDS-PAGE analysis of MFGM-I and MFGM-II milk mucins stained for 
carbohydrate with PAS stain. Freeze dried MFGM-I (100 µg) and MFGM-II (100µg) respectively were 
prepared in reducing gel loading buffer and separated on a 10% SDS-PAGE. The gels were stained for 
carbohydrate with PAS stain. Figure A shows the presence of mucins detected from MFGM-I and MFGM-II 
from HIV positive samples. Lane 1: molecular weight marker. Lanes 2, 4, 6, 8: represents MFGM-I mucins from 
the HIV positive group. Lanes 3, 5, 7, 9: represents MFGM-II mucins from the HIV positive group. Figure B 
shows the presence and absence of mucins in the MFGM-I and MFGM-II respectively from the uninfected 
group. Lane 1: molecular weight marker. Lanes 2, 4, 6: represents MFGM-I mucins from the HIV negative 

























































Figure 3.5 10% SDS-PAGE analysis of MFGM-I and MFGM-II milk samples stained for 
contaminant protein with Coomassie Brilliant Blue R-250. Freeze dried MFGM-I (100 µg) and MFGM-II 
(100µg) respectively were prepared in reducing gel loading buffer and separated on a 10% SDS-PAGE. The gels 
were stained for protein with Coomassie Brilliant Blue R-250.  Figures A and figure B both show the presence of 
proteins in MFGM-I and MFGM-II from the HIV positive (Figures A) and HIV negative (Figures B) sample 
groups. Figure A lane 1: molecular weight marker. Lanes 2, 4, 6, 8: represents contaminant proteins in the 
MFGM-I peak from the HIV positive group. Lanes 3, 5, 7, 9: represents contaminant proteins in the MFGM-II 
peaks from the HIV positive group. Figure B shows the presence and absence of mucins in the MFGM-I and 
MFGM-II respectively from the uninfected group. Lane 1: molecular weight marker.  Lanes 2, 4, 6, 8: represents 
contaminant proteins in the MFGM-I peak from the HIV negative group. Lanes 3, 5, 7, 9 : represents 






















































Figure 3.6 Western blotting analysis of MFGM-I and MFGM-II using mouse anti-MUC1 
monoclonal antibody. Freeze dried MFGM-I (400µg) and MFGM-II (400µg) were separated on 0.7% agarose 
gel electrophoresis and then transferred to a nitrocellulose membrane before blocking overnight. Mouse anti-
MUC1 monoclonal antibody was used as the primary antibody with rabbit anti-mouse horse radish peroxidase as 
the secondary antibody. Lane 1: MUC1 detected in bronchial lavage freeze dried sample. Lane 2: MUC1 
detected in purified cervical mucins. Lanes 3-10 shows the detection of MUC1 in samples from HIV positive, 
while lanes 11-18 shows the presence of MUC1 in MFGM samples from HIV negative patients. Lanes 3, 5, 7, 9:  
represents MUC1 detected in MFGM-I from the HIV positive samples. Lanes 4, 6, 8, 10: represents MUC1 
detected in MFGM-II from the HIV positive samples. Lanes 11, 13, 15, 17: represents MUC1 in MFGM-I from 























11     12       13     14     15     16      17    181      2         3     4     5     6     7     8    9    10      11   12   13  14 5  16    17    18      
 
 
Figure 3.7 Western blotting analysis of MFGM-I and MFGM-II using mouse anti-MUC4 
monoclonal antibody. Freeze dried MFGM-I (400µg) and MFGM-II (400µg)  were separated on a 0.7% 
agarose gel electrophoresis and then transferred to a nitrocellulose membrane before blocking overnight. Mouse 
anti-MUC4 monoclonal antibody was used as the primary antibody with rabbit anti-mouse horse radish 
peroxidase as the secondary antibody. Lane 1: MUC4 detected in bronchial lavage. Lane 2: MUC4 detected in 
purified cervical mucins. Lanes 3-10 shows the detection of MUC4 in samples from HIV positive, while lanes 
11-18 shows the presence of MUC4 in MFGM samples from HIV negative patients. Lanes 3, 5, 7, 9: represents 
MUC4 detected in MFGM-I from the HIV positive samples. Lanes 4, 6, 8, 10: represents MUC4 detected in 
MFGM-II from the HIV positive samples. Lanes 11, 13, 15, 17: represents MUC4 in MFGM-I from the HIV 






















              
 
                
Figure 3.8 CsCl density-gradient centrifugation of HIV positive (A) and HIV negative (B) MFGM-I 
sample material. The purification of mucins after centrifugation step in a CsCl density gradient. Solid CsCl and 
4M GuHCl containing 10mM EDTA, 5mM NEM and 0.05% CHAPS pH 6.5 were added to the semi-purified 
mucin rich MFGM-I obtained from the Sepharose CL-4B gel filtration to give a starting density of 1.39-
1.40g/ml. After centrifugation the tubes were fractionated into 8 equal fractions and an aliquot of each fraction 
was used for density measurements and the estimation of mucin and protein. The figures A and B shows a clear 
separation of proteins detected by Bradford ( ), from the mucin rich fractions 4, 5 and 6 assayed by PAS (













































































































































Figure 3.9 SDS-PAGE analyses of the purified milk mucins from MFGM-I from HIV positive and 
HIV negative samples. The gels were stained with PAS (lanes 1-5) or Coomassie Brilliant Blue (lanes 6-9). 
Lane 1(Molecular weight marker), lanes 2 and 3 (arrow indicates PAS stained mucins on the running  gel from 
the HIV positive purified MFGM-I), lanes 4 and 5 (indicate PAS stained mucins on the stacking gel and from the 
HIV negative purified MFGM-I), lanes 6 and 7 (shows that there were no contaminant protein on gel after 
ultracentrifugation in CsCl density gradient purification from the HIV positive purified MFGM-I sample), lanes 
































symbol umol % 
   Aspartic acid D 7.5 
Threonine T 11.8 
Serine S 11.5 
Glutamic acid E 8.8 
Proline P 17.7 
Glycine G 5.4 
Alanine A 8.0 
Valine V 5.1 
Methionine M 1.1 
Isoleucine I 2.8 
Leucine L 4.3 
Tyrosine Y 1.4 
Phenylalanine F 1.4 
Lysine K 1.4 
Histidine H 10.8 
Arginine R 1.1 
      
 
Table 3.1 Amino acid composition of the HIV positive human breast milk mucins. The peptide 
bonds between the amino acid residues that are present in the mucin protein molecule were hydrolysed 
separated, detected by HPLC and the analysis of the resulting derivatised amino acids which allowed for the 































symbol umol % 
   Aspartic acid D 6.8 
Threonine T 11.0 
Serine S 11.2 
Glutamic acid E 8.9 
Proline P 14.8 
Glycine G 5.8 
Alanine A 7.6 
Valine V 5.0 
Methionine M 0.9 
Isoleucine I 2.7 
Leucine L 4.1 
Tyrosine Y 1.2 
Phenylalanine F 1.2 
Lysine K 3.3 
Histidine H 14.6 
Arginine R 3.7 
      
 
Table 3.2 Amino acid composition of the HIV negative human breast milk mucins. The peptide 
bonds between the amino acid residues that are present in the mucin protein molecule were hydrolysed 
separated, detected by HPLC and the analysis of the resulting derivatised amino acids which allowed for the 
































The work described in this study was done at the University of Manchester in the laboratory 
of Professor David Thornton under the supervision of Dr Karine Rousseau. The aim was to 
investigate the possible changes in the glycosylation of milk mucins in the two groups, 
namely the HIV positive and negative groups. The samples were separated into fractions 
using anion-exchange HPLC which separates the mucin glycoproteins based on their charge. 
Samples of fractions from ion-exchange HPLC were blotted onto nitrocellulose membrane 
(0.20µm pore size) using a Schleicher and Schuell Minifold II slot/dot blot apparatus as 
described by Thornton et al., 1991. Mucin glycoproteins on the slot blots were estimated by 
the periodic acid Schiff (PAS) procedure of Mantle and Allen (1978) and the blots were 
scanned densitometrically. Agarose gel electrophoresis and Western blotting analysis 
confirmed the presence or absence of any glycoforms as the mucins with increasing charge 




4.2.1 The periodic acid (PAS) profiles and agarose gel electrophoresis of fractions from 
the anion-exchange HPLC Mono Q of milk fat globule membrane (MFGM) samples 
 
Freeze dried samples of the MFGM-I were brought into solution with 6M and 4M urea before 
being chromatographed on a Pharmacia MonoQ HR 5/5 ion-exchange column. Aliquots of 
fractions (100μl) from ion-exchange HPLC were blotted on the nitrocellulose membrane 
(0.20µm pore size). Staining of the dot blots with PAS showed the fractionation profiles of 
the mucins from the HIV positive (Figure 4.1A) and negative (Figure 4.2A) groups on the 



















MUC1 in the HIV positive group 
The PAS profile for the HIV positive MFGM samples (Figure 4.1B) shows evidence of three 
major population groups of mucin in this group. The three distinct populations of mucins on 
the chromatogram confirmed the different charge densities of the mucins eluted from the 
MonoQ HR 5/5 column (Figures 4.1B). Population I is from fractions 7-12, population II 
from fractions 15-20 whilst possible population III could be from fractions 26-46 with a few 
small peaks that make population III not as distinct as the peaks that were observed for 
populations I and II (Figure 4.1B). The fractions obtained from the HPLC were subjected to 
agarose gel electrophoresis in order to determine the electrophoretic behavior of these 3 
population groups for MUC1 in the HIV positive group. The gels were blotted onto a 
nitrocellulose membrane before probing with anti-MUC1 antibodies. Three visible 
electrophoretic patterns were observed on the Western blots (Figure 4.3A). 
 
Fractions 8-12, that is population 1 on the chromatogram (Figures 4.1 B) showed bands of 
limited electrophoretic mobility (Figure 4.3A, fractions 6-12) compared to population II, 
(Figure 4.3A, fractions 16-20) which display far greater electrophoretic mobility. The 
Western blot analysis of fractions 26-46 (population III) (Figure 4.3A, fractions 26-46) appear 
as smears, quite different from the mucins of populations I and II. The Western blot analysis 
result confirms the finding from the PAS profile.  
 
MUC4 in the HIV positive group 
When the HIV positive blot was probed with  anti-MUC4 antibody (Figure 4.3B, fractions 6-
44), the presence of MUC4 was shown in fractions 6-12 which all form part of population I 
on the PAS profile (Figure 4.1B). MUC4 was also shown to be present on fractions 26, 38-40 
(Figure 4.3B, fractions 26, 38-40) which could form part of population III. The results show 
that MUC4 is in Population I and III (Figures 4.1B and 4.3B), with electrophoretic mobility 
not as wide as that for MUC1, and with an absence of mucin in population II.  
 
MUC1 in the HIV negative group 
The PAS profiles of the HIV negative MFGM were again divided into 3 populations 
according to their chromatogram profile and elution from the MonoQ HR 5/5  column (Figure 
4.2B). A single distinct population is observed on the PAS profile on fractions 7-16 (Figure 
4.2A) corresponding to population 1 from the MonoQ HR 5/5  column (Figure 4.2B). There 















fractions 43-46 which could be population III (Figure 4.2B). However the Western blot 
analysis of MUC1 from the HIV negative group (Figure 4.4A) showed mucins clearly in 
population I, again of limited electrophoretic mobility, with hardly any detectable mucins for 
populations II and III in keeping with the chromatogram and MonoQ HR 5/5  profile (Figures 
4.2A and B).  The MUC1 mucins in this HIV negative group do not vary in their 
electrophoretic mobility (Figure 4.4A) as much as those of the HIV positive group (Figure 
4.3A).  
 
MUC4 in the HIV negative group 
When the blot was probed with anti-MUC4 antibody (Figure 4.4B), MUC4 was detected on 
fractions 6-14 (Figure 4.4B, fractions 6-14), which form part of population I as shown on the 
PAS profile on figure 4.2B. There seems to be faint traces of MUC4 detected on fractions 30-
34 (Figure 4.4B, fractions 30-34), which could possibly explain the slight peak observed on 
the PAS profile (Figure 4.2B, fraction 30-34). This peak could potentially form population II 
for the HIV negative samples. The explanation of the increased peak observed on fractions 
43-46 on the PAS profile is not known, as neither MUC1 nor MUC4 were detected on those 
fractions by Western blot. This peak (Figure 4.2B, fractions 43-46) could contain some other 
trans-membrane mucin MUC16 that has been reported to be present in human breast milk 
(Hattrup et al., 2008).  
 
4.3 Discussion  
 
Anion exchange chromatography of mucins on a MonoQ HR 5/5 column has been a 
successful method to separate mucins from a single source into different populations on the 
basis of charge. The presence of different glycoforms of particular mucins such as MUC5B in 
asthma have been shown (Thornton et al., 1997). This MUC5B glycoform has been found in 
the mucus obtained from a cadaver of a patient that died in status asthmaticus, suggesting that 
the tenacious plug of mucus that blocked this patient’s airways could be due to the presence 
of that extra MUC5B glycoform. It is important therefore to separate mucins from individual 
samples according to their charge to determine any association between different populations 
of mucin and disease. 
 
Using a combination of dot blots, anion-exchange HPLC and agarose gel electrophoresis 















been shown, whilst in the HIV negative group there was only one population for mucin 
detectable for MUC1. The three mucin populations in the HIV positive group as shown on the 
PAS profile (Figure 4.1) reflects the different levels of sialic acid and/or sulphate substitution 
of the oligosaccharide chains on the mucin (Thornton et al., 1994). The significance of this 
variation of MUC1 in the HIV positive group is yet to be elucidated. However a hint of this 
variation was first seen in the crude preparations of MFGM-1 mucins in that there seemed to 
be larger amounts of MFGM-1 eluting on Sepharose 4B gel filtration for the HIV positive 
group (Fig 3.3A) compared to the HIV negative group (Figure 3.3B) and still more clearly on 
Western blots of HIV positive material for MUC1 in the HIV positive group (Figure 3.6 
fractions 3, 5, 7 and 9) compared to the HIV negative group (Figure 3.6 fractions 11, 13, 15 
and 17). Clearly there always was more detectable mucin (both MUC1 and MUC4 but 
especially MUC1) in the HIV positive group. Figure 3.6A shows very clearly the variation in 
intensity, size of smear and electrophoretic mobility of MUC1 in the MGFM-I material in the 
HIV positive group compared to the HIV negative group (Figure 3.6B). The results in this 
chapter are in keeping with these earlier findings in that MUC1 in the HIV positive group is 
divided into 3 populations, clearly seen by dot blot analysis (Figure 4.1A), the Mono Q 
column profile (Figure 4.1B) and Western blotting against an anti-MUC1 antibody (Figure 
4.3A). This wide variation for MUC1 in the HIV positive group is not seen for the HIV 
negative group (Figures 4.2A and B and Figure 4.4A). Again the HIV positive mucins in the 
crude preparation generally seemed less in amounts (Fig 3.4B, 3.5B and Fig 3.6 fractions 11, 
13, 15 and 17) and had less electrophoretic mobility in the gels. 
 
MUC4 seems to be a less important player in breast milk mucins in HIV-AIDS. Clearly there 
was more of it in the HIV positive group (Figure 3.7 fractions 3, 5, 7 and 9) than in the HIV 
negative group (Figure 3.7, fractions 11, 13, 15 and 17). MUC4 eluted as populations I and 
somewhat III from the anion exchange column and showed some variation in the HIV 
positive group (Figure 4.3B) but hardly any such variation in the HIV negative group (Figure 
4.4B).  
 
All this suggests that in breast milk from HIV positive patients, there is an associated 
variation of MUC1 in terms of different charged populations of mucins and less so of MUC4. 
The HIV negative group has less mucin and even less variation. It is intriguing that this is so 
considering that our laboratory has shown that salivary mucins inhibit HIV-1 in an in vitro 















especially MUC1 in the HIV positive group, should be examined further to determine whether 
there is reduction in mother-to-child transmission of HIV-1. This would require a larger well 
planned study in which breast milk is obtained from HIV positive mothers whose offspring 
may or may not be HIV positive?   
 
Changes in the glycosylation of MUC1 that are associated with cancer have been reported and 
includes the incomplete synthesis of carbohydrate chains, generating new antigens exploitable 
as laboratory diagnostic markers, among which are T(Galβ1→3GalNAc-α1-O-ser/Thr), 
Tn3(GalNAc-α1-O-ser/Thr) and sialyl-Tn antigens, in a variety of cancers (Kannan et al., 
2003). However, limited information is available about the changes in MUC1 glycosylation 
that are associated with HIV-1 infection. This is the first report of a finding that shows the 
presence of MUC1 populations that are associated with HIV-1 infection. 
 
Glycans on the cancer-associated mucin differ from those found on MUC1 that is expressed 
by normal mammary epithelial cells. The normal mucin contains the extended core 2 based 
glycans that are formed when N-acetylglucosamine [GlcNAc] is attached to the GalNAc of 
core 1 [Galβ1-3GalNAc], while on the cancer mucin the glycans can be shorter and core 1 
based, with a high level of sialic acid (Taylor-Papadimitriou et al., 2002). There is no data 
that has yet explained how MUC1 populations occur due to infection with HIV. This study is 
only reporting the presence of these populations. 
 












































Figure 4.1 Anion exchange HPLC of MFGM-I from the HIV positive group. The high-Mr 
glycopeptides were chromatographed on a Pharmacia Mono Q HR 5/5 ion-exchange column. Samples of 
fractions (100μl) from ion-exchange HPLC were blotted on the nitrocellulose membrane (0.20µm pore size) 



















































             




























II (Fractions 30-34) Unidentified
(Fractions 43-46)
 
Figure 4.2 Anion exchange HPLC of MFGM from the HIV negative group. The high-Mr 
glycopeptides were chromatographed on a Pharmacia Mono Q HR 5/5 ion-exchange column. Samples of 
fractions (100μl) from ion-exchange HPLC were blotted on the nitrocellulose membrane (0.20µm pore size) 
(Figure A) before assaying the fractions for neutral sugars using PAS assay (Figure B). 
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Figure 4.3 Agarose gel electrophoresis of fractions from across the Mono Q chromatogram of HIV 
positive MFGM mucins. Aliquots (150μl) of selected fractions from the HPLC were frozen by liquid nitrogen 
and the samples were freeze dried.  The freeze dried samples were subjected to 0.7% (w/v) agarose gel 
electrophoresis and subsequently blotted onto the nitrocellulose membrane before blocking overnight. Mouse 
anti-MUC1 (Figure A fractions 6-46) and anti-MUC4 (Figure B fractions 6-44) monoclonal antibodies were 
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Figure 4.4 Agarose gel electrophoresis of fractions from across the Mono Q chromatogram of HIV 
negative MFGM mucins Aliquots (150μl) of selected fractions from the HPLC were frozen by liquid nitrogen 
and the samples were freeze dried.  The freeze dried samples were subjected to 0.7% (w/v) agarose gel 
electrophoresis and subsequently blotted to the nitrocellulose membrane before blocking overnight. Mouse anti-
MUC1 (Figure A fractions 4-46) and anti-MUC4 (Figure B fractions 4-46) monoclonal antibodies were used as 




















THE ACTIVITY OF CRUDE BREAST MILK (WITH OR WITHOUT  HEAT 
TREATMENT AT 80
o
C,10 MIN) AND PURIFIED MILK MUCINS AGAISNT THE 





The purpose of the study described in this chapter was to determine the anti-HIV activity of 
crude breast milk and its mucin component as well as that of heat treated milk using a 
luciferase reporter gene assay in TZM-bl cells. The principle of the HIV-1 neutralisation 
assay used in this study exploits the use of “pseudoviruses” that incorporate molecularly 
cloned HIV-1 Env into defective virus particles that are capable of only a single round of 
infection. The 293T cells are used as a conduit to generate the pseudoviruses by the co-
transfection with an env-mutated plasmid, along with the env clone of choice; this is then 
used to infect a transformed cell line which expresses the appropriate receptors (Polonis et al., 
2008). Post co-transfection, the generated pseudovirus particles are infectious but are unable 
to produce infectious progeny virions for subsequent rounds of infections. The env-mutated 
plasmid gets transcribed into viral genomic, RNA packaged by the pseudovirions for delivery 
of the tat gene to the TZM-bl cells. Soon after infection, luciferase reporter gene expression is 
induced by viral tat protein. Luciferase activity is then quantified as relative luminescence 
units (RLU) which is directly proportional to the number of infectious virus particles present 
in the inoculum over a wide range of values (Montefiori, 2009). 
 
In this study, the TZM-bl cells were allowed to incubate at 37
o
C for 26 hours before mucin 
samples and viruses were added. The pseudovirus was allowed to incubate with dilutions of 
samples (crude breast milk with or without heat treatment at 80
o
C for 10 min or purified 
mucins) for an hour before adding this mixture to the cultured TZM-bl cells. The luciferase 
activity was measured after 48 hours of culture. 
 The possible cytotoxicity of crude milk and milk mucins against the TZM-bl cells was 
investigated. A study was conducted to determine the proliferative index of these cells by an 


















5.2.1 The activity of crude breast milk (with or without heat treatment at 80
o
C, 10 min) 
and purified milk mucins (MUC1 and MUC4) against the HIV pseudovirus Du422.1. 
 
The anti-HIV activity of the crude breast milk (n=16 from each HIV positive and HIV 
negative groups), heated (80
o
C, 10 min) milk (n=10 from each group), and purified milk 
mucins (n=16 from each group) were tested against the Du422.1 pseudovirus using the 
reporter gene assay in TZM-bl cells. BNAB0044 is an antibody from an HIV infected serum 
sample  which was used as a positive control for neutralization (Fig 5.1-5.3). The results 
show that the positive control neutralized the virus in a dose response manner with 80% 
neutralization at a serum dilution of 1:100. Bovine serum albumin  was used as a negative 
control at a starting concentration of 195ng/ml which neutralised <25% of the viral activity. 
Figure 5.1 shows the representative neutralisation curves of the crude breast milk samples 
against Du422.1 pseudovirus. Crude breast milk from HIV positive donors showed 60% 
neutralisation of the virus, while the HIV negative donor’s milk neutralised the virus at about 
40%. Increased neutralisation of viral activity was seen for the heated (80
o
C for 10 min) milk 
samples (Figure 5.2) with neutralisation of 80% for the HIV positive samples and 70% for the 
HIV negative samples. The purified milk mucins (Figure 5.3) from the HIV positive group 
neutralised 50% of the viral activity, while the HIV negative mucins had much lower 
neutralisation efficacy  (35% neutralisation).  
 
5.2.2 Neutralization potency of the crude breast milk (with or without heat treatment at 
80
o
C, 10 min) and purified milk mucins samples from the HIV positive and HIV 
negative groups against the pseudovirus Du422.1 
 
The neutralization potency of individual samples from each category was assessed and 
summarized (Table 5.1). Non-linear regression using Prism Pad was used to generate the IC50 
values, which is defined as the concentration required to inhibit HIV activity by 50% (Walker 
et al., 2011). For the HIV positive crude breast milk, 10 out of 16 (10/16) (Samples 1-8, 15, 
16) showed exceptional potency with low IC50 values of <10 ng/ml (0.24 -6.55 ng/ml) and 3 
samples had IC50values that were a 100x fold higher (30.38-196.4 ng/ml). We were not able 















crude milk samples, 6 samples (samples 1-2, 7, 10-11, 13) had IC50 values of <10, while 3 
samples had IC50 between 17.88-51.70 ng/ml. The data for sample 12 was not obtained.  
 
Among the HIV positive heated milk samples, only one sample (sample 5) elicited potent 
neutralization with an IC50 of <10, and 2 other samples had higher values (>100ng/ml). IC50 
for samples 3-4, 7, 9 were either not obtained or the IC50 value generated was 0 ng/ml. The 
IC50 values generated for the 3/9 HIV negative heated breast milk were >10 but < 100 ng/ml 
while the other 6 samples had IC50 values of >100 ng/ml.   
 
Only 2 purified mucin samples (samples 2, 10) from HIV positive donors neutralized the virus 
at IC50 <10. We were not able to obtain data for samples 5-6, 11-13. The IC50 values obtained 
for the HIV negative pure mucins showed to have IC50 of > 100 for samples 2, 6-7, 13-15, 
with no data obtained for samples 1, 4, 8, 9, 12. 
 
5.2.3 MTT assay: Analyzing toxicity of crude milk with or without heat treatment (80
o
C, 
10 min) and purified milk mucins.  
 
The toxicity of the human breast milk and purified mucins agaisnt the TZM-bl cells was 
tested by an in-vitro MTT [3-(4, 5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide] 
colorimetric assay. The viable cells were counted by trypan blue dye (1:4 dilution) exclusion 
test and the cell count was adjusted to 1×10
5
 cells/ml. The crude milk, milk mucins and 
heated milk samples from both the HIV positive and HIV negative groups were shown to be 
non-toxic to the TZM-bl cells with viability of ≥ 80% (Figure 5.4). The TZM-bl cells were 
treated with 10% SDS in 0.01M HCl as a negative control and the number of metabolically 




Previous studies (Habte et al., 2008) done in our laboratory showed that purified human milk 
mucins have inhibitory activity against HIV-1 whilst the crude breast milk does not. The work 
that is reported in this chapter seeked to verify the findings of Habte et al., (2008) by utilizing 
a high throughput and validated neutralisation assay that has a high degree of inter-experiment 
reproducibility. The work that was carried out by Habte et al., (2008) had limitations in that 















(Habte et al., 2008) also required the pooling of samples within specific groups (for example 
milk from normal subjects), to successfully purify sufficient amounts of mucin for analysis. 
Another limitation of this study was the absence of a well defined ‘normal’ group. Individuals 
who declared living a ‘risk free’ lifestyle were co-opted to form what we defined as ‘normal’ 
for these studies. 
 
The work reported in this chapter looked at both the HIV positive and HIV negative groups 
with no pooling of sample. The HIV status of those individuals in the Maternity Clinic at 
Groote Schuur Hospital whose human breast milk samples were collected was confirmed by 
the clinicians. 
 
Other studies showed that human breast milk mucins have the ability to protect against the 
rota virus (Yolken et al., 1992) and pox virus (Habte et al., 2007).   When comparing the IC50  
between the 6 groups (Table 5.1), the HIV positive crude breast milk samples seem to have 
more potent neutralisation effect with IC50 values of < 10ng/ml. Most of the samples within 
the same group exhibited differing degrees of overall neutralisation potency. The explanation 
of the higher pseudoviral neutralisation efficacy of the crude milk samples from the HIV 
positive samples could be as a result of the HIV Env-specific secretory IgA, secretory IgM 
and IgG antibodies that have been reported to be present in milk. However, the role of these 
antibodies in the prevention of infant HIV acquisition is still unclear (Fouda et al., 2011). The 
crude breast milk from the HIV negative groups also showed increased neutralisation of the 
pseudovirus. This could be explained by the presence of the molecule lactoferrin in crude 
milk which has been shown to be inhibitory to HIV virus (Berkhout et al., 2002). Crude milk 
also contains glycosaminoglycan moieties that prevent the binding of HIV envelope 
glycoprotein (Newburg et al., 1995). Milk  oligosaccharides that have multiple fucose 
residues and multiple Lewis epitopes have high binding affinity for DC-SIGN and compete 
with HIV-1-gp120 for binding to DC-SIGN (Hong et al., 2008). Using ELISA based assay 
and cell based assay, studies by Hong et al., (2008) showed that human milk oligosaccharides 
(500mg/l) reduced HIV-1-gp120 binding to DC-SIGN by more than 60% and 80% 
respectively. 
 Our results, with respect to the behaviour of crude breast milk are similar to the findings of 
Kazmi et al., (2006), who found that crude breast milk has an HIV inhibitory role. The 
findings are different from those that were reported by Habte et al., 2008 who found that 


















C, 10 min) milk samples showed to be even more effective at neutralising HIV-1 
and the reason for this is not clear. The milk mucins (MUC1 and MUC4) are enclosed in milk 
fat globules (Schroten et al., 1992; Habte et al., 2007). One possibility of the increased viral 
neutralisation could be that these membrane bound mucins have physical contact with the 
virus once they are dislodged from the membrane. The mucins were dislodged from the 
membrane by heating the milk at 80
o
C for 10 min (as previously shown by Buchheim et al., 
1988), and thus were able to interact and possibly neutralise the virus. 
 
Although the results showed that the purified mucins from both groups had far less 
neutralization potency in comparison to the crude milk sample (with or without heat 
treatment), this study also showed that the purified mucins from the HIV positive group had 
higher neutralisation potency than the mucins from the HIV negative group. The reason for 
this is unknown, but could be attributed to a higher content of mucins that were observed in 
the HIV positive samples after the separation with Sepharose CL-4B gel filtration and 
confirmed with Western blotting analysis. It could be that the HIV positive mucins had much 
more MUC1, which is another Lewis-X factor abundantly present in milk, specifically bound 
to DC-sign (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin) 
on DC and effectively blocked DC-sign mediated HIV-1 transmission to T-cells (Saeland et 
al., 2009). The concentration of mucins in the mucous is very low, about 0.5-1% (Creeth, 
1978), this level of mucins might be suppressed in the HIV negative group and increased in 
the positive group and possibly as a defence mechanism. 
  
There was  inter-individual variation noted in the neutralization potency within the crude 
(with or without heat treatment) and purified sample groups. This is why representative 
neutralisation efficacy curves were selected. It should also be noted that invalid IC50 values 
were obtained for some samples. There is a need to verify these findings in another study with 
increased study material numbers. 
 
HIV-1 gains entry into the host cells by means of the CD4 receptor and at least one co-
receptor that is expressed on the surface of the cell membrane. Viral gp 120 bind the CD4 and 
the appropriate co-receptor of the target cells which then results in a conformational change 
and unmasking of a second viral envelope protein called gp41. Viral gp41 interacts with the 















2003). Antibodies such as b12 antibodies have been reported to neutralise by binding to the 
CD4 binding site on the gp120 and therefore stopping the engagement of gp120 and CD4 on 
the cell surface. The blocking of CD4 engagement thus results in the halting of the plasma 
membrane fusion as well as entry into the cell through endocytosis in epithelial cells 
(Schaeffer et al., 2004). The antibody BNAB0044 was used as a positive control in this study. 
 
Certain assay parameters determined the outcome of the neutralisation assay. These include 
the density of the TZM-bl cells used as the target cells, the virus used, the viral/mucin dilution 
or concentration, length of culture time, volumes of components added, duration of pre-
incubation of mucin samples with the virus, duration of infection and the endpoint measured 
(Polonis et al., 2008). The pseudovirus that was used is called Du422.1 from Kwazulu-Natal 
and it is a clade C which is common in South Africa (Binley et al., 2004). According to the 
rank-ordering analysis that was done, the Du422.1 pseudovirus exhibits a distinctively 
sensitive phenotype of neutralising antibody sensitivities as the virus was neutralised by each 
of the plasma pools that were tested. The clustering analysis is the method that is used to 
distinguish four subsets of viruses that are representative of distinct tiers of neutralization 
sensitivity. Viral isolates that demonstrate the greatest sensitivity to neutralisation form their 
own cluster called tier 1A, while those with above-average sensitivities have been termed tier 
1B. The larger subgroup of tiers 2 viral isolates exhibit moderate sensitivity to neutralisation. 
The subgroup of tier 3 viruses is resistant to neutralisation (Seaman et al., 2010). The cells 
that were used in this assay are called TZM-bl cells (also known as JC53BL-13).                                                                                                                                                  
They are CXCR4-positive HeLa cell clones that are engineered to express CD4 and CCR5. 
These cells are further engineered to contain integrated reporter genes for luciferase and 
Escherichia coli β–Galactosidase under control of an HIV long terminal repeat sequence. The 
luciferase reporter allows for automated quantification of HIV infection while the β–
Galactosidase reporter allows for direct enumeration of infectious viral units by counting β–
Gal expression positive infected cell colonies under a microscope (Wei et al., 2002). These 
TZM-bl cells are highly permissible to infection by most HIV strains; including the primary 
HIV-1 isolates (Montefiori, 2005). 
 
In the majority of neutralisation assays, the virus and antibody are pre-incubated then added to 
the CD4+ target cells (Polonis et al., 2008). In this experiment however, seeding cells 26 
hours prior to adding virus and sample was a novel way to reduce the toxicity levels. The 















based on the capacity of the mitochondrial enzyme, succinate dehydrogenase of living cells to 
convert MTT tetrazolium [3-(4, 5-dimethylthiozole-2yl)-2,5-diphenyltetrazolium bromide] 
into a blue coloured product (formazan) that was assayed 5 days post-infection, and is 
proportional to the number of living cells present (Saravanan et al., 2003). The cytotoxicity 
studies were conducted with 1x10
5 
cells per well. The result of the MTT assay showed 
activity in the TZM-bl cells, which is a reflection that the crude breast milk and milk mucins 


















































Figure 5.1 Representative neutralisation dose response curves against HIV-1 subtype C env 
pseudovirus Du422.1 with HIV positive crude breast milk and HIV negative crude breast milk at a 
starting concentration of 195ng/ml.  The antibody BNAB0044 was used as a positive control at a dilution of 
1:100 and bovine serum albumin was used as a negative control at a starting concentration of 195ng/ml. The 
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Figure 5.2 Representative neutralisation dose response curves against HIV-1 subtype C env 
pseudovirus Du422.1 with HIV positive heated breast milk and HIV negative heated breast milk at a 
starting concentration of 195ng/ml.  The antibody BNAB0044 was used as a positive control at a dilution of 
1:100 and bovine serum albumin was used as a negative control at a starting concentration of 195ng/ml. The 
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Figure 5.3 Representative neutralisation dose response curves against HIV-1 subtype C env 
pseudovirus Du422.1 with HIV positive purified milk mucins and HIV negative purified milk mucins at a 
starting concentration of 195ng/ml.  The antibody BNAB0044 was used as a positive control at a dilution of 
1:100 and bovine serum albumin was used as a negative control at a starting concentration of 195ng/ml. The 






























Sample concentration ng/ml 
Negative control (Bovine 
serum albumin) 
Positive control (BNAB0044 
antibody) 
Purified milk mucins (HIV +) 
Purified milk mucins (HIV -) 
























IC50 (50% Inhibition of DU4221 pseudovirus) 
  Crude human breast milk 
Heated (80
o
C, 10 min) breast 
milk Purified milk mucins 
  HIV positive HIV negative HIV positive HIV negative HIV positive 
HIV 
negative 
Sample 1 0.83 6.5 183.2 932.3 91.75   
Sample 2 3.14 0.02 unavailable 162.1 0.03 516400000 
Sample 3 5.52 96673 >195 30.47 25.27 unavailable 
Sample 4 0.25 5567   97.3 >195   
Sample 5 0.72 458 0.8956 111.9 Interrupted unavailable 
Sample 6 0.04 unavailable 74 161.9 Interrupted 22558 
Sample 7 1.77 1.03 >195 117.5 478.5 61083 
Sample 8 0.93 113.2 394 93.49 48625   
Sample 9 Interrupted 17.88 0 515 70.52   
Sample 10 >195 0.02     2.12 30.41 
Sample 11 Interrupted 0.02     unavailable 
0.00000236
2 
Sample 12 30.38 Not converged     >195   
Sample 13 196.4 7.7       124887 
Sample 14 170.6 44.95     2216 1205 
Sample 15 0.24 51.7     15.21 1891 
Sample 16 6.55 196.5     22.62 56.25 
              
 
Table 5.1 IC50 values of crude breast milk with or without heat treatment (80
o
C, 10 min) and 
purified milk mucins against HIV-1 subtype C env pseudovirus Du422.1. IC50 <10 ng/ml, IC50>10 ng/ml and 


























         
Figure 5.4 The response of TZM-bl cells to varying concentrations of crude breast milk with or 
without heat treatment (80
o
C, 10 min) and purified milk mucins from the HIV positive and HIV negative 




































Sample concentration (ng/ml)  
TZM-bl cells treated with 
10%SDS in 0.01M HCL 
Human breast milk (HIV +) 
Human breast milk (HIV -) 
Purified  mucins (HIV +) 
Purified  mucins (HIV -) 
Heated breast milk (HIV +) 



















Mucus is synthesized by specialized goblet cells of the columnar epithelium that lines the 
major internal tracts of the body that are exposed to the external environment. The 
malfunctioning of the mucus has been implicated in the etiology of many diseases, such as 
peptic ulceration, ulcerative colitis, bronchitis, infertility and external disorders of the eye 
(Allen, A. 1983). It contains proteins such as lysozyme, immunoglobulins, defensins, growth 
factors and trefoil factors which serve a defensive purpose (Gipson et al., 1997).  
 
Mucin polymeric molecules contribute to the visco-elastic gel properties of mucus. Human 
breast milk contains numerous biologically active compounds such as mucins and 
glycosaminoglycans, which protect breast-fed infants from bacteria, viruses and toxins (Habte 
et al., 2007). Reports indicated that there are two human milk mucins, namely MUC1 which 
is best characterised and the second milk mucin called MUC4.  Both MUC1 and MUC4 are 
tethered trans-membrane mucins which can act as a second line of defence and are anti-
adhesive proteins. They have a crucial role in regulating many cellular functions, including 
cell proliferation and apoptosis of T-cells and are involved in cell signalling and 
immunoregulation. These mucins also play a role as pathological markers. Both have a 
potential role in pathogen adhesion (Wilson et al., 2008). MUC1 has been reported to 
effectively block HIV-1 transmission to T-cells (Saeland et al., 2009; Habte et al., 2008). 
 
South Africa is reported to have more human immunodeficiency virus infected people than in 
any other country in the world, with a national HIV prevalence of 11.4% (Jaspan et al., 2006). 
HIV-1 subtype C is the predominant HIV-1 genotype in Southern Africa and is rapidly 
spreading throughout the world (Ndung’u et al., 2006) and accounts for approximately 50% 
of paediatric HIV-1 infections (Zhang et al., 2006). Breast-feeding maintains the maternal-
foetal immunologic link after birth which may favour the immuno-competence transmission 
from the mother to her infant. However, mother-to-child transmission of HIV-1 through 
breast feeding accounts for the majority of HIV-1 infections among infants as high as 40% 
















The biological objectives of this study were to isolate, purify and identify mucins in human 
breast milk and to compare mucins from normal and infected breast milk with respect to their 
inhibition of the HI virus. This study investigated the possible changes in the glycosylation of 
milk mucins. The study also tested the anti-HIV-1 activity of crude breast milk with or 
without heat treatment, (80
o
C, 10 min), and its purified mucin components, namely MUC1 
and MUC4, in HIV positive patients compared with those who are not infected.  
 
Milk mucins were isolated from the prepared milk fat globule membrane by Sepharose CL-4B 
gel filtration column. The Sepharose CL-4B column elution profiles for the HIV positive and 
HIV negative groups showed that the MFGM have two mucin rich peaks. The first peak 
named MFGM-I was eluted in the void volume while the second peak named MFGM-II 
eluted in the included volume.  The HIV positive elution profile had two large distinct peaks 
while the HIV negative elution profile showed one small peak and one large peak. When the 
MFGM-I and MFGM-II peaks were separated on SDS-PAGE and stained for carbohydrate by 
PAS, The SDS-PAGE gel from the HIV positive showed the presence of increased staining 
intensity of mucins in comparison to the HIV negative gel. The MFGM-I peaks from both 
groups showed more intensely stained mucins than the MFGM-II peaks.  
 
The identity of the mucins in the MFGM-I and MFGM-II peaks was confirmed by Western 
blotting analysis to be MUC1 and MUC4. Both MUC1 and MUC4 were present in each 
MFGM-I and MFGM-II peaks from the HIV positive and HIV negative groups. 
Intense staining was seen in the MFGM-I peak for MUC1 in the HIV positive group than the 
MFGM-II peak. The HIV negative group had far less material in both the MFGM-I and 
MFGM-II peaks with the MFGM-II peaks hardly visible at all. 
 
MFGM-I peaks from the HIV positive and HIV negative groups were further purified by 
isopycnic density gradient centrifugation in caesium chloride and 4M guanidinium chloride. 
The purification profiles showed a clear separation between the lower density proteins and the 
higher density mucin fractions which were assayed by PAS. And the identity of mucins in 
MFGM-I from both groups was further confirmed by amino acid analysis which showed the 
presence of increased serine, threonine and proline. There were no differences between the 
amount of serine threonine and proline for the HIV positive group which added up to 41% of 

















In order to investigate populations, MFGM samples were chromatographed on a Pharmacia 
Mono Q HR 5/5 ion-exchange HPLC. Samples of fractions from ion-exchange HPLC were 
blotted on the nitrocellulose membrane (0.20µm pore size) before assaying the fractions for 
neutral sugars using a solution PAS assay.  
 
The PAS profile for the HIV positive MFGM-1 showed evidence of three populations. The 
agarose gel electrophoresis showed that MUC1 had two distinct population I and population II 
on the same fractions as the PAS profiles based on the two visible electrophoretic patterns that 
were observed on the blots. One other possible population III of MUC1 was also noted and 
appeared as smears on the Western blot. Varying populations for MUC4 mucins in the HIV 
positive samples were observed on the Western blot. MUC4 was present on fractions which 
formed part of population I on the PAS profile. It was also present on fractions which formed 
population III at a lower density. 
 
The PAS profiles of MFGM-I from the HIV negative samples showed less variation in this 
group compared to those of the HIV positive group. A single distinct population I was 
observed on the PAS profile, as well as one other minor population II. A third minor peak was 
observed as well which could be another potential population. Agarose gels verified that 
MUC1 was detected on fractions of population I shown on the PAS profile. When the blot 
was probed with anti-MUC4 antibody, MUC4 was detected on fractions of population I. 
There seems to be faint traces of MUC4 detected on fractions of population II which explains 
the slight peak observed on the PAS profile. There is no explanation known to us of the third 
peak observed on the PAS profile as neither MUC1 nor MUC4 were detected on those 
fractions by Western blot. 
 
The crude breast milk samples showed 60% neutralisation for the HIV positive samples, 
while the HIV negative milk neutralised at 40%. The purified milk mucins from the HIV 
positive group neutralised 50% of the viral activity, while the HIV negative mucins had much 
lower neutralisation efficacy with 35% neutralisation. Increased neutralisation of viral activity 
was seen for the heated milk samples with neutralisation of 80% for the HIV positive samples 
















The results in this study are intriguing in that firstly they differ from a previous study in our 
laboratory (Habte et al., 2007) which showed that normal crude milk samples did not inhibit 
the virus while the purified mucins did. This work had the added advantage of comparing 
crude milk and purified mucin from normal and infected milk and further found that 
inhibition of HIV-1 was greater by infected samples, both crude and purified. This certainly 
needs further investigation together with the very crucial observation that milk heated prior to 
the assay had an increased inhibitory activity against HIV-1. This finding could have 
enormous implications for mother-to-child transmission of the virus through breast-feeding, a 
significant contributor to the pandemic in sub-Saharan Africa. 
 
All in all this study has established the crucial role of mucins in the inhibition of the virus that 
causes AIDS. Whilst such a study requires more development in terms of numbers and size 
and a wider investigation, the implications of our study need to be considered. 
 
Secreted mucins are known for their gel-forming properties and their contribution to forming 
unstirred crude gels on epithelial surfaces to which they afford protection and also keep these 
surfaces moist in the most hostile of environments (Allen 1981, Mall 2008). Considering that 
mucins inhibit the HI virus in an in vitro assay not only in breast milk but in saliva too (where 
work in our laboratory has pinpointed the crucial role salivary mucus and mucin play in 
preventing transmission of the virus by the exchange of oral fluids (Habte et al., 2006), we 
ask whether mucins could be used as a basis for a formula that could be used as a vaginal and 
anal microbicide to prevent transmission of the virus through sexual intercourse. 
 
Future work in our laboratory will be guided by such considerations as outlined above, whilst 
we continue to investigate in greater depth the characteristics of mucus and mucins from the 
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We are doing a study on the mucus produced in your breast milk. Mucus is a sticky 
substance mixed with bodily secretions and is necessary for lubrication and protection 
of the tracts in the body. We wish to find out the role of mucus in the breast milk of 
HIV negative and positive individuals. 
 
We need to take 200 ml of milk from you to use in an experiment which will 





1. We will need to take your folder number (NOT YOUR NAME) from which 
we will get details of your age, gender and origin. All this information will be 
kept absolutely confidential and we promise not to use your sample for any 
other purpose but that we have described.  
2. You have a right to say that you do not wish to take part in this study. If you 
do not wish to be part of the study, this will not affect the treatment you 
receive.  
3. If you agree to participate in this research project now and then decide at a 
later time that you do not wish to continue, that is also fine. That decision will 
once again not affect your right to treatment and care.  
4. It is possible that we will publish the findings of this study but your name will 
not be mentioned.  
 
If there are any queries, please refer them to your surgeon/clinician. If you think of 
any queries at a later date, please don’t hesitate to contact me at the telephone number 
below. 
 

























REQUEST FOR BREAST MILK SAMPLE TO MEASURE THE EFFECT OF MUCUS ON 
THE HI VIRUS 
 
Research Laboratory 
Division of General Surgery 
OMB Groote Schuur Hospital 
UCT Medical School, Observatory  7925  
 
Tel: (021) 406 6168/6227  Fax: (021) 448 6461 
 
 
Please fill in all the information requested: 
 
Folder No.   ___________________________________________ 
 
Sex:   M             F             
 
Date of Birth   Year: ________   Month: ________ Day: ________          Ethnic Origin:  
_________________________________ 
 
Contact Address: Hospital/Clinic where samples are taken 
 
Town:  _____________________________  Fax: _____________________ 
 
                                                                        Tel: _____________________ 
 
 
For Laboratory use only: 
 
 
Date Received: YY _________  DD __________  Computer Index No.: __________________ 
 
CONSENT FOR BREAST MILK SAMPLE 
 
1. I, _______________________________________________ give permission that my 
breast milk be taken for research purposes in the investigation of HIV AIDS. 
 
2. I give permission that a portion of the sample be stored indefinitely for: 
a) possible re-analysis; 
b) research purposes, subject to the approval of the University of Cape Town 
Research Ethics Committee, provided that any information from such 
research will remain confidential. 
 
3. I authorize / do not authorize my doctor(s) (DELETE WHERE NOT APPLICABLE) to 
provide relevant clinical details to the researchers. 
 
 
ALL OF THE ABOVE HAS BEEN FULLY EXPLAINED TO ME IN A LANGUAGE 
THAT I UNDERSTAND AND MY QUESTIONS ANSWERED 
___________________________ 
Please note that 
your HIV status 
is not recorded 
on this form. 
AP  
 

















C. MUCIN  ISOLATION, PURIFICATION AND CHARACTERIZATION  
a. 10mM phosphate buffer(PBS): 
A. 10mM  Na2PO4 (Mw 141.96)   0.568gms/400ml 
B. 10mM  NaH2PO4 (Mw 119.98) 0.9598gms/800ml 




b. Salt azide buffer: 
0.2 NaCl (Mw 58.44) 11.69gms/litre 
0.02%    NaN3 (Mw)    0.2gms/litre 
 
c. 6M Guanidinium hydrochloride in PBS pH 6.5 
6M GuHCl (Mw 95.5)  573.0g/litre PBS pH 6.5 
 
d.  Protease inhibitors: (P.I.) 
1mM Iodoacetamide 0.0925gms/500ml 
5mM Benzamidine  0.437 gms/500ml 
10mM EDTA  1.8612 gms/500ml 
1mM PMSF   0.087gms/500ml 
100mM Hexanoic Acid 0.656gms/500ml 
1mg/litre Trypsin inhibitor 0.5mg/500ml 
5mM NEM   0.3128gms/500ml  
 
e. Periodic acid Schiff (PAS) assay for glycoproteins in mucin 
10g Pararosaniline hydrochloride 
1litre boiling distilled water 
Stir continuously, and then cool to 50
o
C 
Add 200ml 1M HCl  
Allow to mature in the dark overnight 
Add 30g activated charcoal 
Stir for 5-60 minutes 
Filter to remove charcoal 
Add 30g activated charcoal 















The resulting red solution is stored at room temperature in a dark bottle. 
 
Decolorized Schiff reagent (Make fresh for every assay) 
100mg Sodium metabisulphite  in 6ml schiff’s reagent  
Incubate at 37
o
C until the solution is colorless 
 
Periodic acid solution 
10ml 7% Acetic acid and 20ul periodic acid 
 
Assay for a microtitre plate 
20ul Sample/fraction 
100ul Periodic acid solution 
Incubate at 37
o
C for 1 hour 
Add 200ul decolorized Schiff’s reagent 
Incubate at room temperature for 30 mins 
Read absorbance at 555nm and plot graph 
 
f. Lowry method for protein estimation 
Solution A: 2% anhydrous sodium carbonate 
  2gms Na2CO3 in 100 ml 0.1 M NaOH 
  Make fresh 
Solution B: (1) 0.25gms CuSO4 in 25ml distilled water 
  (2) 0.5gms Sodium tartrate in 25 ml distilled water 
  Keep at 4
o
C and make as needed in 1:2 diltution to give working sol B 
Solution C: 1ml working solution B to 50ml solution A made up just before using 
Folins solution: Dilute 1: 2 with distilled water 
Assay for a microtitre plate 
10ul Sample  
10ul 0.1M NaOH 
200ul Solution C 
Mix and incubate at 25
o
C for 10 min 
20ul diluted Folins reagent 
Mix and incubate at 25
o
C for 30 min 

















a. Buffers for  SDS PAGE 
BIS/Acrylamide:  30g Acrylamide 
   0.8 g BIS 
   Make up to 100ml with distilled water, store at 4
o
C in a dark bottle  
Running gel buffer: 0.75M [(hydroxymethyl) aminomethane] Tris 
   0.2% SDS 
   In distilled water and pH 8.8 and store at 4
o
C 
Spacer gel buffer: 0.25M Tris 
   0.2% SDS 
   Distilled water and pH 6.8 and store at 4
o
C 
Tank/Reservoir Buffer: 0.025M Tris 
    0.19M Glycine 
    0.1% SDS 
    In distilled water and pH 8.8 and store at room temperature 
Sample application buffer: 2% SDS 
    10% Glycerol 
    0.01% Bromophenol blue 
Add 5% Mercaptoethanol for a reducing buffer, boil sample buffer for 1 min before loading 
TEMED: use as it is 
 
  
   
b. SDS PAGE 
10% Running gel  Mini gel 
30% Bis/Acrylamide  3.67ml 
0.1% SDS   3.90ml 
Running buffer  3.60ml 
AMPS    100ul 
TEMED   3ul 
Spacer gel 
30% Bis/Acrylamide  0.5ml 















AMPS    73ul 
TEMED   5ul 
 
c. Coomassie blue stain for protein on proteins 
0.1% Coomassie blue 
30% Methanol  
10% Glacial acetic Acid 
Method: 
Place gel in Coomassie blue stain and shake gently overnight. Destain with 20% methanol 
acetic acid solution until gels are clearly visible. Wash in distilled water and photograph. 
 
d. Periodic Acid Schiff (PAS) gel staining  
Schiff’s reagent: 
Dissolve 1g pararosanniline in 200ml rapidly boiling distilled water, stirring constantly 
Cool on bench to 50
o
C 
Add 20ml 1M HCl  
Cool to 25
o
C and add 1 g potassium metabisulphide and leave to stand for 12-24hrs in the 
dark 
Add 2g activated charcoal 
Mix for 1 min and then filter 
Store at 25
o
C in a dark bottle 
Method: 
Place gel in 50% ethanol for 30 min 
Wash in distilled water for 10 min 
Place gel in 1% periodic acid made up in 3% acetic acid for 30 min 
Wash in distilled water for 30 min or overnight 
Place gel in 0.1 sodium metabisulphite in 10mM HCl for 2X10 mins 
Place gel in Schiff’s reagent in the dark for 60 min 
Then in 0.1 sodium metabisulphite in 10mM HCl in the dark 
 
e. Buffers for agarose gel electrophoresis and western blotting 
50X TAE:   
242g Tris 















100 ml 0.5M EDTA (18361g) 
pH to 8.0 and make up to 1 litre with distilled water 
 
Running buffer: 
1X TAE containing 0.1% SDS (w/v) 
 
20XSSC: 
1402.4g sodium chloride 
705.6g tri-sodium citrate 





Sample loading buffer: 
40-50% glycerol 
1X TAE 
Smidgen Bromophenol blue 
 
TBST 
10mM Tris-HCl 1.21g 
150mM NaCl 8.76g 
0.05% Tween 20 0.5ml 
pH to 8.0 and make up to 1liter with distilled water 
 
Agarose Gel   
0.7 % Agarose type V  
1X TAE 
0.1% SDS 
Boil till dissolved, cool and then pour into gel apparatus with the required comb. 
 
E. Pseudoviral neutralization assay 
















2.5 FCS or FBS 
0.5ml 1M HEPES 
50μl 10ng/ μl Gentamycin 
 
F. Glycoform detection using anion exchange HPLC 
a. 6M clean urea 
Dissolve 720g urea in 2L distilled water 
Add charcoal and stir 
Filter- using Whatman paper (2 x big and 1 x small) 
Add a couple of spatula of mixed bed resin 
Filter through a 0.2μm membrane (1 x nitrocellulose, 1 x nylon together) 
b. Buffer A for HPLC 
10mM piperazine/perchlorate 
 
c. Buffer B for HPLC 
10mM piperazine/perchlorate 
0.5M Lithium chloride 
 
 
 
 
 
 
 
